{
    "abstract": " Persistent human papillomavirus (HPV) infection is causally linked to the development of several human cancers, including cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers. To address the need for a therapeutic vaccine against HPV-associated diseases, here we test and compare the immunogenicity and therapeutic efficacy of a bacterial exotoxin fusion protein covalently linked to the HPV16 E7 oncoprotein adjuvanted with CpG or GPI-0100 in the C3.43 preclinical HPV16-transformed tumor model. We show that TVGV-1 protein vaccine adjuvanted with either CpG or GPI-0100 adjuvant induces a high frequency of E7-specific CD8 + T cells, and both adjuvants are able to assist the immune response in inducing polyfunctional cytokine-secreting lytic T cells that show therapeutic efficacy against well-established C3.43 tumors. CpG-adjuvanted TVGV-1 resulted in higher frequencies of IFN\u03b3 secreting and degranulating E7-specific T cells compared to GPI-0100-adjuvanted TVGV-1, resulting in marginally increased in vivo efficacy. Despite minor differences in immune response outcomes, we consider both CpG ODN and GPI-0100 to be promising vaccine adjuvants to increase the immunogenicity and therapeutic efficacy of the TVGV-1 protein for HPV16-driven cancers. ",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Formana"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "de Martel"
                },
                {
                    "first": "Charles J.",
                    "initial": "C.J.",
                    "last": "Lacey"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Soerjomatarama"
                },
                {
                    "first": "Joannie",
                    "initial": "J.",
                    "last": "Lortet-Tieulent"
                },
                {
                    "first": "Laia",
                    "initial": "L.",
                    "last": "Bruni"
                },
                {
                    "first": "Jerome",
                    "initial": "J.",
                    "last": "Vignat"
                },
                {
                    "first": "Jacques",
                    "initial": "J.",
                    "last": "Ferlay"
                },
                {
                    "first": "Freddie",
                    "initial": "F.",
                    "last": "Bray"
                },
                {
                    "first": "Martyn",
                    "initial": "M.",
                    "last": "Plummer"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Franceschi"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.07.055",
            "firstpage": "F12",
            "issn": "0264410X",
            "lastpage": "F23",
            "pmid": "23199955",
            "pub_year": 2012,
            "title": "Global burden of human papillomavirus and related diseases",
            "volume": "30"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "de Sanjose"
                },
                {
                    "first": "Wim G.V.",
                    "initial": "W.G.V.",
                    "last": "Quint"
                },
                {
                    "first": "Laia",
                    "initial": "L.",
                    "last": "Alemany"
                },
                {
                    "first": "Daan T.",
                    "initial": "D.T.",
                    "last": "Geraets"
                },
                {
                    "first": "Jo Ellen",
                    "initial": "J.E.",
                    "last": "Klaustermeier"
                },
                {
                    "first": "Belen",
                    "initial": "B.",
                    "last": "Lloveras"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Tous"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Felix"
                },
                {
                    "first": "Luis Eduardo",
                    "initial": "L.E.",
                    "last": "Bravo"
                },
                {
                    "first": "Hai Rim",
                    "initial": "H.R.",
                    "last": "Shin"
                },
                {
                    "first": "Carlos S.",
                    "initial": "C.S.",
                    "last": "Vallejos"
                },
                {
                    "first": "Patricia Alonso",
                    "initial": "P.A.",
                    "last": "de Ruiz"
                },
                {
                    "first": "Marcus Aurelho",
                    "initial": "M.A.",
                    "last": "Lima"
                },
                {
                    "first": "Nuria",
                    "initial": "N.",
                    "last": "Guimera"
                },
                {
                    "first": "Omar",
                    "initial": "O.",
                    "last": "Clavero"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Alejo"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Llombart-Bosch"
                },
                {
                    "first": "Chou",
                    "initial": "C.",
                    "last": "Cheng-Yang"
                },
                {
                    "first": "Silvio Alejandro",
                    "initial": "S.A.",
                    "last": "Tatti"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Kasamatsu"
                },
                {
                    "first": "Ermina",
                    "initial": "E.",
                    "last": "Iljazovic"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Odida"
                },
                {
                    "first": "Rodrigo",
                    "initial": "R.",
                    "last": "Prado"
                },
                {
                    "first": "Muhieddine",
                    "initial": "M.",
                    "last": "Seoud"
                },
                {
                    "first": "Magdalena",
                    "initial": "M.",
                    "last": "Grce"
                },
                {
                    "first": "Alp",
                    "initial": "A.",
                    "last": "Usubutun"
                },
                {
                    "first": "Asha",
                    "initial": "A.",
                    "last": "Jain"
                },
                {
                    "first": "Gustavo Adolfo Hernandez",
                    "initial": "G.A.H.",
                    "last": "Suarez"
                },
                {
                    "first": "Luis Estuardo",
                    "initial": "L.E.",
                    "last": "Lombardi"
                },
                {
                    "first": "Aekunbiola",
                    "initial": "A.",
                    "last": "Banjo"
                },
                {
                    "first": "Clara",
                    "initial": "C.",
                    "last": "Men\u00e9ndez"
                },
                {
                    "first": "Efr\u00e9n Javier",
                    "initial": "E.J.",
                    "last": "Domingo"
                },
                {
                    "first": "Julio",
                    "initial": "J.",
                    "last": "Velasco"
                },
                {
                    "first": "Ashrafun",
                    "initial": "A.",
                    "last": "Nessa"
                },
                {
                    "first": "Saibua C.Bunnag",
                    "initial": "S.C.B.",
                    "last": "Chichareon"
                },
                {
                    "first": "You Lin",
                    "initial": "Y.L.",
                    "last": "Qiao"
                },
                {
                    "first": "Enrique",
                    "initial": "E.",
                    "last": "Lerma"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Garland"
                },
                {
                    "first": "Toshiyuki",
                    "initial": "T.",
                    "last": "Sasagawa"
                },
                {
                    "first": "Annabelle",
                    "initial": "A.",
                    "last": "Ferrera"
                },
                {
                    "first": "Doudja",
                    "initial": "D.",
                    "last": "Hammouda"
                },
                {
                    "first": "Luciano",
                    "initial": "L.",
                    "last": "Mariani"
                },
                {
                    "first": "Adela",
                    "initial": "A.",
                    "last": "Pelayo"
                },
                {
                    "first": "Ivo",
                    "initial": "I.",
                    "last": "Steiner"
                },
                {
                    "first": "Esther",
                    "initial": "E.",
                    "last": "Oliva"
                },
                {
                    "first": "Chris J.L.M.",
                    "initial": "C.J.L.M.",
                    "last": "Meijer"
                },
                {
                    "first": "Waleed Fahad",
                    "initial": "W.F.",
                    "last": "Al-Jassar"
                },
                {
                    "first": "Eugenia",
                    "initial": "E.",
                    "last": "Cruz"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Wright"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Puras"
                },
                {
                    "first": "Cecilia Ladines",
                    "initial": "C.L.",
                    "last": "Llave"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Tzardi"
                },
                {
                    "first": "Theodoros",
                    "initial": "T.",
                    "last": "Agorastos"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Garcia-Barriola"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Clavel"
                },
                {
                    "first": "Jaume",
                    "initial": "J.",
                    "last": "Ordi"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "And\u00fajar"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Castellsagu\u00e9"
                },
                {
                    "first": "Gloria I.",
                    "initial": "G.I.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "Andrzej Marcin",
                    "initial": "A.M.",
                    "last": "Nowakowski"
                },
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Bornstein"
                },
                {
                    "first": "Nubia",
                    "initial": "N.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "F. Xavier",
                    "initial": "F.X.",
                    "last": "Bosch"
                }
            ],
            "doi": "10.1016/S1470-2045(10)70230-8",
            "firstpage": "1048",
            "issn": "14702045",
            "lastpage": "1056",
            "pmid": "20952254",
            "pub_year": 2010,
            "title": "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study",
            "volume": "11"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Serrano"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "De Sanjos\u00e9"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Tous"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiros"
                },
                {
                    "first": "Nubia",
                    "initial": "N.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Bosch"
                },
                {
                    "first": "Laia",
                    "initial": "L.",
                    "last": "Alemany"
                }
            ],
            "doi": "10.1016/j.ejca.2015.06.001",
            "firstpage": "1732",
            "issn": "09598049",
            "lastpage": "1741",
            "pmid": "26121913",
            "pub_year": 2015,
            "title": "Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions",
            "volume": "51"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Aimee R.",
                    "initial": "A.R.",
                    "last": "Kreimer"
                },
                {
                    "first": "Gary M.",
                    "initial": "G.M.",
                    "last": "Clifford"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Boyle"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Franceschi"
                }
            ],
            "doi": "10.1158/1055-9965.EPI-04-0551",
            "firstpage": "467",
            "issn": "10559965",
            "lastpage": "475",
            "pmid": "15734974",
            "pub_year": 2005,
            "title": "Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systemic review",
            "volume": "14"
        },
        "b0025": {
            "authors": [
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Doorbar"
                },
                {
                    "first": "Wim",
                    "initial": "W.",
                    "last": "Quint"
                },
                {
                    "first": "Lawrence",
                    "initial": "L.",
                    "last": "Banks"
                },
                {
                    "first": "Ignacio G.",
                    "initial": "I.G.",
                    "last": "Bravo"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Stoler"
                },
                {
                    "first": "Tom R.",
                    "initial": "T.R.",
                    "last": "Broker"
                },
                {
                    "first": "Margaret A.",
                    "initial": "M.A.",
                    "last": "Stanley"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.06.083",
            "firstpage": "F55",
            "issn": "0264410X",
            "lastpage": "F70",
            "pub_year": 2012,
            "title": "The biology and life-cycle of human papillomaviruses",
            "volume": "30"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Joseph G.",
                    "initial": "J.G.",
                    "last": "Skeate"
                },
                {
                    "first": "Andrew W.",
                    "initial": "A.W.",
                    "last": "Woodham"
                },
                {
                    "first": "Mark H.",
                    "initial": "M.H.",
                    "last": "Einstein"
                },
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Da Silva"
                },
                {
                    "first": "W. Martin",
                    "initial": "W.M.",
                    "last": "Kast"
                }
            ],
            "doi": "10.1080/21645515.2015.1136039",
            "firstpage": "1418",
            "issn": "21645515",
            "lastpage": "1429",
            "pmid": "26835746",
            "pub_year": 2016,
            "title": "Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases",
            "volume": "12"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Aleyo",
                    "initial": "A.",
                    "last": "Chabeda"
                },
                {
                    "first": "Romana J.R.",
                    "initial": "R.J.R.",
                    "last": "Yanez"
                },
                {
                    "first": "Renate",
                    "initial": "R.",
                    "last": "Lamprecht"
                },
                {
                    "first": "Ann E.",
                    "initial": "A.E.",
                    "last": "Meyers"
                },
                {
                    "first": "Edward P.",
                    "initial": "E.P.",
                    "last": "Rybicki"
                },
                {
                    "first": "Inga I.",
                    "initial": "I.I.",
                    "last": "Hitzeroth"
                }
            ],
            "doi": "10.1016/j.pvr.2017.12.006",
            "firstpage": "46",
            "issn": "24058521",
            "lastpage": "58",
            "pmid": "29277575",
            "pub_year": 2018,
            "title": "Therapeutic vaccines for high-risk HPV-associated diseases",
            "volume": "5"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Chao Wei",
                    "initial": "C.W.",
                    "last": "Liao"
                },
                {
                    "first": "Chi An",
                    "initial": "C.A.",
                    "last": "Chen"
                },
                {
                    "first": "Chien Nan",
                    "initial": "C.N.",
                    "last": "Lee"
                },
                {
                    "first": "Yi Ning",
                    "initial": "Y.N.",
                    "last": "Su"
                },
                {
                    "first": "Ming Cheng",
                    "initial": "M.C.",
                    "last": "Chang"
                },
                {
                    "first": "Ming Houg",
                    "initial": "M.H.",
                    "last": "Syu"
                },
                {
                    "first": "Chang Yao",
                    "initial": "C.Y.",
                    "last": "Hsieh"
                },
                {
                    "first": "Wen Fang",
                    "initial": "W.F.",
                    "last": "Cheng"
                }
            ],
            "doi": "10.1158/0008-5472.CAN-05-0958",
            "firstpage": "9089",
            "issn": "00085472",
            "lastpage": "9098",
            "pmid": "16204084",
            "pub_year": 2005,
            "title": "Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects",
            "volume": "65"
        },
        "b0045": {
            "authors": [
                {
                    "first": "T. J.",
                    "initial": "T.J.",
                    "last": "Goletz"
                },
                {
                    "first": "K. R.",
                    "initial": "K.R.",
                    "last": "Klimpel"
                },
                {
                    "first": "S. H.",
                    "initial": "S.H.",
                    "last": "Leppla"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Keith"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Berzofsky"
                }
            ],
            "doi": "10.1016/S0198-8859(97)00081-5",
            "firstpage": "129",
            "issn": "01988859",
            "lastpage": "136",
            "pmid": "9297531",
            "pub_year": 1997,
            "title": "Delivery of antigens to the MHC class I pathway using bacterial toxins",
            "volume": "54"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Thomas W.",
                    "initial": "T.W.",
                    "last": "Dubensky"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.1016/j.smim.2010.04.007",
            "firstpage": "155",
            "issn": "10445323",
            "lastpage": "161",
            "pmid": "20488726",
            "pub_year": 2010,
            "title": "Adjuvants for cancer vaccines",
            "volume": "22"
        },
        "b0055": {
            "authors": [
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Marciani"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Press"
                },
                {
                    "first": "R. C.",
                    "initial": "R.C.",
                    "last": "Reynolds"
                },
                {
                    "first": "A. K.",
                    "initial": "A.K.",
                    "last": "Pathak"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Pathak"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Gundy"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Farmer"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Koratich"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "May"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00118-3",
            "firstpage": "3141",
            "issn": "0264410X",
            "lastpage": "3151",
            "pmid": "10856794",
            "pub_year": 2000,
            "title": "Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity",
            "volume": "18"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Dante J.",
                    "initial": "D.J.",
                    "last": "Marciani"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Reynolds"
                },
                {
                    "first": "Ashish K.",
                    "initial": "A.K.",
                    "last": "Pathak"
                },
                {
                    "first": "Kyra",
                    "initial": "K.",
                    "last": "Finley-Woodman"
                },
                {
                    "first": "Richard D.",
                    "initial": "R.D.",
                    "last": "May"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00298-6",
            "firstpage": "3961",
            "issn": "0264410X",
            "lastpage": "3971",
            "pmid": "12922132",
            "pub_year": 2003,
            "title": "Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100",
            "volume": "21"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Soo Kie",
                    "initial": "S.K.",
                    "last": "Kim"
                },
                {
                    "first": "Govindaswami",
                    "initial": "G.",
                    "last": "Ragupathi"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Cappello"
                },
                {
                    "first": "Ella",
                    "initial": "E.",
                    "last": "Kagan"
                },
                {
                    "first": "Philip O.",
                    "initial": "P.O.",
                    "last": "Livingston"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00195-X",
            "firstpage": "530",
            "issn": "0264410X",
            "lastpage": "537",
            "pmid": "11027818",
            "pub_year": 2000,
            "title": "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates",
            "volume": "19"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Govindaswami",
                    "initial": "G.",
                    "last": "Ragupathi"
                },
                {
                    "first": "Don M.",
                    "initial": "D.M.",
                    "last": "Coltart"
                },
                {
                    "first": "Lawrence J.",
                    "initial": "L.J.",
                    "last": "Williams"
                },
                {
                    "first": "Fusataka",
                    "initial": "F.",
                    "last": "Koide"
                },
                {
                    "first": "Ella",
                    "initial": "E.",
                    "last": "Kagan"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Allen"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Harris"
                },
                {
                    "first": "Peter W.",
                    "initial": "P.W.",
                    "last": "Glunz"
                },
                {
                    "first": "Philip O.",
                    "initial": "P.O.",
                    "last": "Livingston"
                },
                {
                    "first": "Samuel J.",
                    "initial": "S.J.",
                    "last": "Danishefsky"
                }
            ],
            "doi": "10.1073/pnas.202427599",
            "firstpage": "13699",
            "issn": "00278424",
            "lastpage": "13704",
            "pmid": "12359877",
            "pub_year": 2002,
            "title": "On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines",
            "volume": "99"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Zhang"
                },
                {
                    "first": "Qiu Bo",
                    "initial": "Q.B.",
                    "last": "Yang"
                },
                {
                    "first": "Dante J.",
                    "initial": "D.J.",
                    "last": "Marciani"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Martin"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clements"
                },
                {
                    "first": "Suzanne M.",
                    "initial": "S.M.",
                    "last": "Michalek"
                },
                {
                    "first": "Jannet",
                    "initial": "J.",
                    "last": "Katz"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00438-9",
            "firstpage": "4459",
            "issn": "0264410X",
            "lastpage": "4471",
            "pmid": "14505929",
            "pub_year": 2003,
            "title": "Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis",
            "volume": "21"
        },
        "b0080": {
            "authors": [
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Kensil"
                },
                {
                    "first": "J. Y.",
                    "initial": "J.Y.",
                    "last": "Wu"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Soltysik"
                }
            ],
            "doi": "10.1007/978-1-4615-1823-5_22",
            "firstpage": "525",
            "issn": "10780467",
            "lastpage": "541",
            "pmid": "7551234",
            "pub_year": 1995,
            "title": "Structural and immunological characterization of the vaccine adjuvant QS-21.",
            "volume": "6"
        },
        "b0085": {
            "authors": [
                {
                    "first": "J. Y.",
                    "initial": "J.Y.",
                    "last": "Wu"
                },
                {
                    "first": "B. H.",
                    "initial": "B.H.",
                    "last": "Gardner"
                },
                {
                    "first": "C. I.",
                    "initial": "C.I.",
                    "last": "Murphy"
                },
                {
                    "first": "J. R.",
                    "initial": "J.R.",
                    "last": "Seals"
                },
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Kensil"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Recchia"
                },
                {
                    "first": "G. A.",
                    "initial": "G.A.",
                    "last": "Beltz"
                },
                {
                    "first": "G. W.",
                    "initial": "G.W.",
                    "last": "Newman"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Newman"
                }
            ],
            "firstpage": "1519",
            "issn": "00221767",
            "lastpage": "1525",
            "pmid": "1538134",
            "pub_year": 1992,
            "title": "Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine",
            "volume": "148"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Susan F.",
                    "initial": "S.F.",
                    "last": "Slovin"
                },
                {
                    "first": "Govind",
                    "initial": "G.",
                    "last": "Ragupathi"
                },
                {
                    "first": "Celina",
                    "initial": "C.",
                    "last": "Fernandez"
                },
                {
                    "first": "Matthew P.",
                    "initial": "M.P.",
                    "last": "Jefferson"
                },
                {
                    "first": "Meghan",
                    "initial": "M.",
                    "last": "Diani"
                },
                {
                    "first": "Andrew S.",
                    "initial": "A.S.",
                    "last": "Wilton"
                },
                {
                    "first": "Shemeeakah",
                    "initial": "S.",
                    "last": "Powell"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Spassova"
                },
                {
                    "first": "Celso",
                    "initial": "C.",
                    "last": "Reis"
                },
                {
                    "first": "Henrick",
                    "initial": "H.",
                    "last": "Clausen"
                },
                {
                    "first": "Samuel",
                    "initial": "S.",
                    "last": "Danishefsky"
                },
                {
                    "first": "Philip",
                    "initial": "P.",
                    "last": "Livingston"
                },
                {
                    "first": "Howard I.",
                    "initial": "H.I.",
                    "last": "Scher"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.01.072",
            "firstpage": "3114",
            "issn": "0264410X",
            "lastpage": "3122",
            "pub_year": 2005,
            "title": "A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: A study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21",
            "volume": "23"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Arthur M.",
                    "initial": "A.M.",
                    "last": "Krieg"
                },
                {
                    "first": "Ae Kyung",
                    "initial": "A.K.",
                    "last": "Yi"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Matson"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Waldschmidt"
                },
                {
                    "first": "Gail A.",
                    "initial": "G.A.",
                    "last": "Bishop"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Teasdale"
                },
                {
                    "first": "Gary A.",
                    "initial": "G.A.",
                    "last": "Koretzky"
                },
                {
                    "first": "Dennis M.",
                    "initial": "D.M.",
                    "last": "Klinman"
                }
            ],
            "doi": "10.1038/374546a0",
            "firstpage": "546",
            "issn": "00280836",
            "lastpage": "549",
            "pmid": "7700380",
            "pub_year": 1995,
            "title": "CpG motifs in bacterial DNA trigger direct B-cell activation",
            "volume": "374"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Bauer"
                },
                {
                    "first": "Carsten J.",
                    "initial": "C.J.",
                    "last": "Kirschning"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "H\u00e4cker"
                },
                {
                    "first": "Vanessa",
                    "initial": "V.",
                    "last": "Redecke"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Hausmann"
                },
                {
                    "first": "Shizuo",
                    "initial": "S.",
                    "last": "Akira"
                },
                {
                    "first": "Hermann",
                    "initial": "H.",
                    "last": "Wagner"
                },
                {
                    "first": "Grayson B.",
                    "initial": "G.B.",
                    "last": "Lipford"
                }
            ],
            "doi": "10.1073/pnas.161293498",
            "firstpage": "9237",
            "issn": "00278424",
            "lastpage": "9242",
            "pmid": "11470918",
            "pub_year": 2001,
            "title": "Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition",
            "volume": "98"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Bode"
                },
                {
                    "first": "Gan",
                    "initial": "G.",
                    "last": "Zhao"
                },
                {
                    "first": "Folkert",
                    "initial": "F.",
                    "last": "Steinhagen"
                },
                {
                    "first": "Takeshi",
                    "initial": "T.",
                    "last": "Kinjo"
                },
                {
                    "first": "Dennis M.",
                    "initial": "D.M.",
                    "last": "Klinman"
                }
            ],
            "doi": "10.1586/erv.10.174",
            "firstpage": "499",
            "issn": "14760584",
            "lastpage": "511",
            "pmid": "21506647",
            "pub_year": 2011,
            "title": "CpG DNA as a vaccine adjuvant",
            "volume": "10"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Krug"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Rothenfusser"
                },
                {
                    "first": "Veit",
                    "initial": "V.",
                    "last": "Hornung"
                },
                {
                    "first": "Bernd",
                    "initial": "B.",
                    "last": "Jahrsdrfer"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Blackwell"
                },
                {
                    "first": "Zuhair K.",
                    "initial": "Z.K.",
                    "last": "Ballas"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Endres"
                },
                {
                    "first": "Arthur M.",
                    "initial": "A.M.",
                    "last": "Krieg"
                },
                {
                    "first": "Gunther",
                    "initial": "G.",
                    "last": "Hartmann"
                }
            ],
            "doi": "10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U",
            "firstpage": "2154",
            "issn": "00142980",
            "lastpage": "2163",
            "pmid": "11449369",
            "pub_year": 2001,
            "title": "Identification of CpG oligonucleotide sequences with high induction of IFN-\u03b1/\u03b2 in plasmacytoid dendritic cells",
            "volume": "31"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Mariet C.W.",
                    "initial": "M.C.W.",
                    "last": "Feltkamp"
                },
                {
                    "first": "Henk L.",
                    "initial": "H.L.",
                    "last": "Smits"
                },
                {
                    "first": "Michel P.M.",
                    "initial": "M.P.M.",
                    "last": "Vierboom"
                },
                {
                    "first": "Ren\u00e9 P.",
                    "initial": "R.P.",
                    "last": "Minnaar"
                },
                {
                    "first": "Barteld M.",
                    "initial": "B.M.",
                    "last": "De Jongh"
                },
                {
                    "first": "Jan Wouter",
                    "initial": "J.W.",
                    "last": "Drijfhout"
                },
                {
                    "first": "Jan Ter",
                    "initial": "J.T.",
                    "last": "Schegget"
                },
                {
                    "first": "Cornelis J.M.",
                    "initial": "C.J.M.",
                    "last": "Melief"
                },
                {
                    "first": "W. Martin",
                    "initial": "W.M.",
                    "last": "Kast"
                }
            ],
            "doi": "10.1002/eji.1830230929",
            "firstpage": "2242",
            "issn": "00142980",
            "lastpage": "2249",
            "pmid": "7690326",
            "pub_year": 1993,
            "title": "Vaccination with cytotoxic T lymphocyte epitope\u2010containing peptide protects against a tumor induced by human papillomavirus type 16\u2010transformed cells",
            "volume": "23"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Kent A.",
                    "initial": "K.A.",
                    "last": "Smith"
                },
                {
                    "first": "Brenna L.",
                    "initial": "B.L.",
                    "last": "Meisenburg"
                },
                {
                    "first": "Victor L.",
                    "initial": "V.L.",
                    "last": "Tam"
                },
                {
                    "first": "Robb R.",
                    "initial": "R.R.",
                    "last": "Pagarigan"
                },
                {
                    "first": "Raymond",
                    "initial": "R.",
                    "last": "Wong"
                },
                {
                    "first": "Diljeet K.",
                    "initial": "D.K.",
                    "last": "Joea"
                },
                {
                    "first": "Liz",
                    "initial": "L.",
                    "last": "Lantzy"
                },
                {
                    "first": "Mayra A.",
                    "initial": "M.A.",
                    "last": "Carrillo"
                },
                {
                    "first": "Todd M.",
                    "initial": "T.M.",
                    "last": "Gross"
                },
                {
                    "first": "Uriel M.",
                    "initial": "U.M.",
                    "last": "Malyankar"
                },
                {
                    "first": "Chih Sheng",
                    "initial": "C.S.",
                    "last": "Chiang"
                },
                {
                    "first": "Diane M.",
                    "initial": "D.M.",
                    "last": "Da Silva"
                },
                {
                    "first": "Thomas M.",
                    "initial": "T.M.",
                    "last": "K\u00fcndig"
                },
                {
                    "first": "W. Martin",
                    "initial": "W.M.",
                    "last": "Kast"
                },
                {
                    "first": "Zhiyong",
                    "initial": "Z.",
                    "last": "Qiu"
                },
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Bot"
                }
            ],
            "doi": "10.1158/1078-0432.CCR-09-0645",
            "firstpage": "6167",
            "issn": "10780432",
            "lastpage": "6176",
            "pmid": "19789304",
            "pub_year": 2009,
            "title": "Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors",
            "volume": "15"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Jinno"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ogata"
                },
                {
                    "first": "V. K.",
                    "initial": "V.K.",
                    "last": "Chaudhary"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Willingham"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Adhya"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "FitzGerald"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Pastan"
                }
            ],
            "firstpage": "15953",
            "issn": "00219258",
            "lastpage": "15959",
            "pmid": "2506173",
            "pub_year": 1989,
            "title": "Domain II mutants of pseudomonas exotoxin deficient in translocation",
            "volume": "264"
        },
        "b0130": {
            "authors": [
                {
                    "first": "V. K.",
                    "initial": "V.K.",
                    "last": "Chaudhary"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Jinno"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "FitzGerald"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Pastan"
                }
            ],
            "doi": "10.1073/pnas.87.1.308",
            "firstpage": "308",
            "issn": "00278424",
            "lastpage": "312",
            "pmid": "2104981",
            "pub_year": 1990,
            "title": "Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity",
            "volume": "87"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Chia Yen",
                    "initial": "C.Y.",
                    "last": "Huang"
                },
                {
                    "first": "Chi An",
                    "initial": "C.A.",
                    "last": "Chen"
                },
                {
                    "first": "Chien Nan",
                    "initial": "C.N.",
                    "last": "Lee"
                },
                {
                    "first": "Ming Cheng",
                    "initial": "M.C.",
                    "last": "Chang"
                },
                {
                    "first": "Yi Ning",
                    "initial": "Y.N.",
                    "last": "Su"
                },
                {
                    "first": "Yi Chun",
                    "initial": "Y.C.",
                    "last": "Lin"
                },
                {
                    "first": "Chang Yao",
                    "initial": "C.Y.",
                    "last": "Hsieh"
                },
                {
                    "first": "Wen Fang",
                    "initial": "W.F.",
                    "last": "Cheng"
                }
            ],
            "doi": "10.1016/j.ygyno.2007.06.031",
            "firstpage": "404",
            "issn": "00908258",
            "lastpage": "412",
            "pmid": "17905417",
            "pub_year": 2007,
            "title": "DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens",
            "volume": "107"
        },
        "b0140": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Peng"
                },
                {
                    "first": "T. T.",
                    "initial": "T.T.",
                    "last": "Tomson"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Trimble"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "He"
                },
                {
                    "first": "C. F.",
                    "initial": "C.F.",
                    "last": "Hung"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Wu"
                }
            ],
            "doi": "10.1038/sj.gt.3302646",
            "firstpage": "257",
            "issn": "09697128",
            "lastpage": "265",
            "pmid": "16177818",
            "pub_year": 2006,
            "title": "A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects",
            "volume": "13"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Pr\u00e9ville"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Ladant"
                },
                {
                    "first": "Benedikt",
                    "initial": "B.",
                    "last": "Timmerman"
                },
                {
                    "first": "Claude",
                    "initial": "C.",
                    "last": "Leclerc"
                }
            ],
            "firstpage": "641",
            "issn": "00085472",
            "lastpage": "649",
            "pmid": "15695409",
            "pub_year": 2005,
            "title": "Eradication of established tumors by vaccinaton with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein",
            "volume": "65"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Shaochun",
                    "initial": "S.",
                    "last": "Chen"
                },
                {
                    "first": "Chaowei",
                    "initial": "C.",
                    "last": "Liao"
                },
                {
                    "first": "Yiukay",
                    "initial": "Y.",
                    "last": "Lai"
                },
                {
                    "first": "Yan",
                    "initial": "Y.",
                    "last": "Fan"
                },
                {
                    "first": "Gang",
                    "initial": "G.",
                    "last": "Lu"
                },
                {
                    "first": "Hua",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Xiaoai",
                    "initial": "X.",
                    "last": "Zhang"
                },
                {
                    "first": "Marie C.M.",
                    "initial": "M.C.M.",
                    "last": "Lin"
                },
                {
                    "first": "Shuilong",
                    "initial": "S.",
                    "last": "Leng"
                },
                {
                    "first": "Hsiang Fu",
                    "initial": "H.F.",
                    "last": "Kung"
                }
            ],
            "doi": "10.1093/abbs/gmt121",
            "firstpage": "6",
            "issn": "16729145",
            "lastpage": "14",
            "pmid": "24240707",
            "pub_year": 2014,
            "title": "De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin",
            "volume": "46"
        },
        "b0155": null,
        "b0160": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Alberta",
                    "initial": "A.",
                    "last": "Di Pasquale"
                }
            ],
            "doi": "10.1080/21645515.2016.1225635",
            "firstpage": "19",
            "issn": "21645515",
            "lastpage": "33",
            "pmid": "27636098",
            "pub_year": 2017,
            "title": "From discovery to licensure, the Adjuvant System story",
            "volume": "13"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Hong Xiang",
                    "initial": "H.X.",
                    "last": "Sun"
                },
                {
                    "first": "Yong",
                    "initial": "Y.",
                    "last": "Xie"
                },
                {
                    "first": "Yi Ping",
                    "initial": "Y.P.",
                    "last": "Ye"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.01.091",
            "firstpage": "1787",
            "issn": "0264410X",
            "lastpage": "1796",
            "pmid": "19208455",
            "pub_year": 2009,
            "title": "Advances in saponin-based adjuvants",
            "volume": "27"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Dante J.",
                    "initial": "D.J.",
                    "last": "Marciani"
                },
                {
                    "first": "Charlotte R.",
                    "initial": "C.R.",
                    "last": "Kensil"
                },
                {
                    "first": "Gerald A.",
                    "initial": "G.A.",
                    "last": "Beltz"
                },
                {
                    "first": "Chung ho",
                    "initial": "C.h.",
                    "last": "Hung"
                },
                {
                    "first": "Joelle",
                    "initial": "J.",
                    "last": "Cronier"
                },
                {
                    "first": "Andre",
                    "initial": "A.",
                    "last": "Aubert"
                }
            ],
            "doi": "10.1016/0264-410X(91)90262-5",
            "firstpage": "89",
            "issn": "0264410X",
            "lastpage": "96",
            "pmid": "1647576",
            "pub_year": 1991,
            "title": "Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats",
            "volume": "9"
        },
        "b0180": {
            "authors": [
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Newman"
                },
                {
                    "first": "J. Y.",
                    "initial": "J.Y.",
                    "last": "Wu"
                },
                {
                    "first": "B. H.",
                    "initial": "B.H.",
                    "last": "Gardner"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Anderson"
                },
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Kensil"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Recchia"
                },
                {
                    "first": "R. T.",
                    "initial": "R.T.",
                    "last": "Coughlin"
                },
                {
                    "first": "M. F.",
                    "initial": "M.F.",
                    "last": "Powell"
                }
            ],
            "doi": "10.1016/S0264-410X(96)00293-9",
            "firstpage": "1001",
            "issn": "0264410X",
            "lastpage": "1007",
            "pmid": "9261947",
            "pub_year": 1997,
            "title": "Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations",
            "volume": "15"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Yves",
                    "initial": "Y.",
                    "last": "Horsmans"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Marcelle",
                    "initial": "M.",
                    "last": "Van Mechelen"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Van Belle"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Hanon"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Wettendorff"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.12.038",
            "firstpage": "1375",
            "issn": "0264410X",
            "lastpage": "1386",
            "pmid": "18272264",
            "pub_year": 2008,
            "title": "Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers",
            "volume": "26"
        },
        "b0190": {
            "authors": [
                {
                    "first": "F. N.",
                    "initial": "F.N.",
                    "last": "Santos"
                },
                {
                    "first": "G. P.",
                    "initial": "G.P.",
                    "last": "Borja-Cabrera"
                },
                {
                    "first": "L. M.",
                    "initial": "L.M.",
                    "last": "Miyashiro"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Grechi"
                },
                {
                    "first": "A. B.",
                    "initial": "A.B.",
                    "last": "Reis"
                },
                {
                    "first": "M. A.B.",
                    "initial": "M.A.B.",
                    "last": "Moreira"
                },
                {
                    "first": "O. A.",
                    "initial": "O.A.",
                    "last": "Martins Filho"
                },
                {
                    "first": "M. C.R.",
                    "initial": "M.C.R.",
                    "last": "Luvizotto"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Menz"
                },
                {
                    "first": "L. M.",
                    "initial": "L.M.",
                    "last": "Pess\u00f4a"
                },
                {
                    "first": "P. R.",
                    "initial": "P.R.",
                    "last": "Gon\u00e7alves"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Palatnik"
                },
                {
                    "first": "C. B.",
                    "initial": "C.B.",
                    "last": "Palatnik-de-Sousa"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.06.005",
            "firstpage": "6176",
            "issn": "0264410X",
            "lastpage": "6190",
            "pmid": "17630055",
            "pub_year": 2007,
            "title": "Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune\u00ae vaccine",
            "volume": "25"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Thomas G.",
                    "initial": "T.G.",
                    "last": "Evans"
                },
                {
                    "first": "M. Juliana",
                    "initial": "M.J.",
                    "last": "McElrath"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Matthews"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Montefiori"
                },
                {
                    "first": "Kent",
                    "initial": "K.",
                    "last": "Weinhold"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Wolff"
                },
                {
                    "first": "Michael C.",
                    "initial": "M.C.",
                    "last": "Keefer"
                },
                {
                    "first": "Esper G.",
                    "initial": "E.G.",
                    "last": "Kallas"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Corey"
                },
                {
                    "first": "Geoffrey J.",
                    "initial": "G.J.",
                    "last": "Gorse"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Belshe"
                },
                {
                    "first": "Barney S.",
                    "initial": "B.S.",
                    "last": "Graham"
                },
                {
                    "first": "Paul W.",
                    "initial": "P.W.",
                    "last": "Spearman"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Schwartz"
                },
                {
                    "first": "Mark J.",
                    "initial": "M.J.",
                    "last": "Mulligan"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Goepfert"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Fast"
                },
                {
                    "first": "Phi",
                    "initial": "P.",
                    "last": "Berman"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Powell"
                },
                {
                    "first": "Don",
                    "initial": "D.",
                    "last": "Francis"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00415-1",
            "firstpage": "2080",
            "issn": "0264410X",
            "lastpage": "2091",
            "pmid": "11228380",
            "pub_year": 2001,
            "title": "QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans",
            "volume": "19"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Amato"
                },
                {
                    "first": "Aditya",
                    "initial": "A.",
                    "last": "Shetty"
                },
                {
                    "first": "Yingjuan",
                    "initial": "Y.",
                    "last": "Lu"
                },
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Ellis"
                },
                {
                    "first": "Philip S.",
                    "initial": "P.S.",
                    "last": "Low"
                }
            ],
            "doi": "10.1097/CJI.0b013e3182917f59",
            "firstpage": "268",
            "issn": "15249557",
            "lastpage": "275",
            "pmid": "23603861",
            "pub_year": 2013,
            "title": "A phase i study of Folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma",
            "volume": "36"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Amato"
                },
                {
                    "first": "Aditya",
                    "initial": "A.",
                    "last": "Shetty"
                },
                {
                    "first": "Yingjuan",
                    "initial": "Y.",
                    "last": "Lu"
                },
                {
                    "first": "P. Ron",
                    "initial": "P.R.",
                    "last": "Ellis"
                },
                {
                    "first": "Virginia",
                    "initial": "V.",
                    "last": "Mohlere"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Carnahan"
                },
                {
                    "first": "Philip S.",
                    "initial": "P.S.",
                    "last": "Low"
                }
            ],
            "doi": "10.1097/CJI.0000000000000029",
            "firstpage": "237",
            "issn": "15249557",
            "lastpage": "244",
            "pmid": "24714357",
            "pub_year": 2014,
            "title": "A phase I/Ib study of folate immune (EC90 vaccine administered with gpi-0100 adjuvant followed by EC17) with interferon-\u03b1 and interleukin-2 in patients with renal cell carcinoma",
            "volume": "37"
        },
        "b0210": {
            "authors": [
                {
                    "first": "Sam",
                    "initial": "S.",
                    "last": "Jackson"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Lentino"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Kopp"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Murray"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Ellison"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Rhee"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Shockey"
                },
                {
                    "first": "Lalith",
                    "initial": "L.",
                    "last": "Akella"
                },
                {
                    "first": "Kimberly",
                    "initial": "K.",
                    "last": "Erby"
                },
                {
                    "first": "William L.",
                    "initial": "W.L.",
                    "last": "Heyward"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Adams"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Bolshoun"
                },
                {
                    "first": "Tami",
                    "initial": "T.",
                    "last": "Bruce"
                },
                {
                    "first": "Rita",
                    "initial": "R.",
                    "last": "Chuang"
                },
                {
                    "first": "Donna",
                    "initial": "D.",
                    "last": "DeSantis"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fiel"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Fitzgibbons"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Francyk"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Geisberg"
                },
                {
                    "first": "Son",
                    "initial": "S.",
                    "last": "Giep"
                },
                {
                    "first": "Narendra",
                    "initial": "N.",
                    "last": "Godbole"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Haas"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Halpern"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Inzerello"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Jennings"
                },
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Kaiser"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Kay"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Kirby"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Lending"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Levins"
                },
                {
                    "first": "Clifford",
                    "initial": "C.",
                    "last": "Molin"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Noss"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Kotek"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Reynolds"
                },
                {
                    "first": "Ernie",
                    "initial": "E.",
                    "last": "Riffer"
                },
                {
                    "first": "Douglas",
                    "initial": "D.",
                    "last": "Schumacher"
                },
                {
                    "first": "Randall",
                    "initial": "R.",
                    "last": "Severance"
                },
                {
                    "first": "Royce",
                    "initial": "R.",
                    "last": "Solano"
                },
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Tejada"
                },
                {
                    "first": "Leslie",
                    "initial": "L.",
                    "last": "Tharenos"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Throne"
                },
                {
                    "first": "Merle",
                    "initial": "M.",
                    "last": "Turner"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Wolf"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Woodruff"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2017.12.038",
            "firstpage": "668",
            "issn": "0264410X",
            "lastpage": "674",
            "pmid": "29289383",
            "pub_year": 2018,
            "title": "Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults",
            "volume": "36"
        },
        "b0215": {
            "authors": [
                {
                    "first": "J\u00f6rg",
                    "initial": "J.",
                    "last": "Vollmer"
                },
                {
                    "first": "Arthur M.",
                    "initial": "A.M.",
                    "last": "Krieg"
                }
            ],
            "doi": "10.1016/j.addr.2008.12.008",
            "firstpage": "195",
            "issn": "0169409X",
            "lastpage": "204",
            "pmid": "19211030",
            "pub_year": 2009,
            "title": "Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists",
            "volume": "61"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Clive S.",
                    "initial": "C.S.",
                    "last": "Zent"
                },
                {
                    "first": "Brian J.",
                    "initial": "B.J.",
                    "last": "Smith"
                },
                {
                    "first": "Zuhair K.",
                    "initial": "Z.K.",
                    "last": "Ballas"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Wooldridge"
                },
                {
                    "first": "Brian K.",
                    "initial": "B.K.",
                    "last": "Link"
                },
                {
                    "first": "Timothy G.",
                    "initial": "T.G.",
                    "last": "Call"
                },
                {
                    "first": "Tait D.",
                    "initial": "T.D.",
                    "last": "Shanafelt"
                },
                {
                    "first": "Deborah A.",
                    "initial": "D.A.",
                    "last": "Bowen"
                },
                {
                    "first": "Neil E.",
                    "initial": "N.E.",
                    "last": "Kay"
                },
                {
                    "first": "Thomas E.",
                    "initial": "T.E.",
                    "last": "Witzig"
                },
                {
                    "first": "George J.",
                    "initial": "G.J.",
                    "last": "Weiner"
                }
            ],
            "doi": "10.3109/10428194.2011.608451",
            "firstpage": "211",
            "issn": "10428194",
            "lastpage": "217",
            "pmid": "21812536",
            "pub_year": 2012,
            "title": "Phase i clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia",
            "volume": "53"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Hirsh"
                },
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "Paz-Ares"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Boyer"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Rosell"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Middleton"
                },
                {
                    "first": "Wilfried E.E.",
                    "initial": "W.E.E.",
                    "last": "Eberhardt"
                },
                {
                    "first": "Aleksandra",
                    "initial": "A.",
                    "last": "Szczesna"
                },
                {
                    "first": "Pavel",
                    "initial": "P.",
                    "last": "Reiterer"
                },
                {
                    "first": "Mansoor",
                    "initial": "M.",
                    "last": "Saleh"
                },
                {
                    "first": "Oscar",
                    "initial": "O.",
                    "last": "Arrieta"
                },
                {
                    "first": "Emilio",
                    "initial": "E.",
                    "last": "Bajetta"
                },
                {
                    "first": "Roy T.",
                    "initial": "R.T.",
                    "last": "Webb"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "Raats"
                },
                {
                    "first": "Rebecca J.",
                    "initial": "R.J.",
                    "last": "Benner"
                },
                {
                    "first": "Camilla",
                    "initial": "C.",
                    "last": "Fowst"
                },
                {
                    "first": "Sandra J.",
                    "initial": "S.J.",
                    "last": "Meech"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Readett"
                },
                {
                    "first": "Joan H.",
                    "initial": "J.H.",
                    "last": "Schiller"
                }
            ],
            "doi": "10.1200/JCO.2010.32.8971",
            "firstpage": "2667",
            "issn": "0732183X",
            "lastpage": "2674",
            "pmid": "21632509",
            "pub_year": 2011,
            "title": "Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer",
            "volume": "29"
        },
        "b0230": {
            "authors": [
                {
                    "first": "Wim H.J.",
                    "initial": "W.H.J.",
                    "last": "Kruit"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Suciu"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Dreno"
                },
                {
                    "first": "Laurent",
                    "initial": "L.",
                    "last": "Mortier"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Robert"
                },
                {
                    "first": "Vanna",
                    "initial": "V.",
                    "last": "Chiarion-Sileni"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Maio"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Testori"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Dorval"
                },
                {
                    "first": "Jean Jacques",
                    "initial": "J.J.",
                    "last": "Grob"
                },
                {
                    "first": "Juergen C.",
                    "initial": "J.C.",
                    "last": "Becker"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Spatz"
                },
                {
                    "first": "Alexander M.M.",
                    "initial": "A.M.M.",
                    "last": "Eggermont"
                },
                {
                    "first": "Jamila",
                    "initial": "J.",
                    "last": "Louahed"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric F.",
                    "initial": "F.F.",
                    "last": "Lehmann"
                },
                {
                    "first": "Vincent G.",
                    "initial": "V.G.",
                    "last": "Brichard"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Keilholz"
                }
            ],
            "doi": "10.1200/JCO.2012.43.7111",
            "firstpage": "2413",
            "issn": "0732183X",
            "lastpage": "2420",
            "pmid": "23715572",
            "pub_year": 2013,
            "title": "Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma",
            "volume": "31"
        },
        "b0235": {
            "authors": [
                {
                    "first": "Craig L.",
                    "initial": "C.L.",
                    "last": "Slingluff"
                },
                {
                    "first": "Gina R.",
                    "initial": "G.R.",
                    "last": "Petroni"
                },
                {
                    "first": "Walter C.",
                    "initial": "W.C.",
                    "last": "Olson"
                },
                {
                    "first": "Mark E.",
                    "initial": "M.E.",
                    "last": "Smolkin"
                },
                {
                    "first": "Kimberly A.",
                    "initial": "K.A.",
                    "last": "Chianese-Bullock"
                },
                {
                    "first": "Ileana S.",
                    "initial": "I.S.",
                    "last": "Mauldin"
                },
                {
                    "first": "Kelly T.",
                    "initial": "K.T.",
                    "last": "Smith"
                },
                {
                    "first": "Donna H.",
                    "initial": "D.H.",
                    "last": "Deacon"
                },
                {
                    "first": "Nikole E.",
                    "initial": "N.E.",
                    "last": "Varhegyi"
                },
                {
                    "first": "Sean B.",
                    "initial": "S.B.",
                    "last": "Donnelly"
                },
                {
                    "first": "Caroline M.",
                    "initial": "C.M.",
                    "last": "Reed"
                },
                {
                    "first": "Kristy",
                    "initial": "K.",
                    "last": "Scott"
                },
                {
                    "first": "Nadejda V.",
                    "initial": "N.V.",
                    "last": "Galeassi"
                },
                {
                    "first": "William W.",
                    "initial": "W.W.",
                    "last": "Grosh"
                }
            ],
            "doi": "10.1007/s00262-015-1770-9",
            "firstpage": "25",
            "issn": "03407004",
            "lastpage": "36",
            "pmid": "26581199",
            "pub_year": 2016,
            "title": "A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites",
            "volume": "65"
        },
        "b0240": {
            "authors": [
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Dreno"
                },
                {
                    "first": "John F.",
                    "initial": "J.F.",
                    "last": "Thompson"
                },
                {
                    "first": "Bernard Mark",
                    "initial": "B.M.",
                    "last": "Smithers"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Santinami"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Jouary"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Gutzmer"
                },
                {
                    "first": "Evgeny",
                    "initial": "E.",
                    "last": "Levchenko"
                },
                {
                    "first": "Piotr",
                    "initial": "P.",
                    "last": "Rutkowski"
                },
                {
                    "first": "Jean Jacques",
                    "initial": "J.J.",
                    "last": "Grob"
                },
                {
                    "first": "Sergii",
                    "initial": "S.",
                    "last": "Korovin"
                },
                {
                    "first": "Kamil",
                    "initial": "K.",
                    "last": "Drucis"
                },
                {
                    "first": "Florent",
                    "initial": "F.",
                    "last": "Grange"
                },
                {
                    "first": "Laurent",
                    "initial": "L.",
                    "last": "Machet"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Hersey"
                },
                {
                    "first": "Ivana",
                    "initial": "I.",
                    "last": "Krajsova"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Testori"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Conry"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Guillot"
                },
                {
                    "first": "Wim H.J.",
                    "initial": "W.H.J.",
                    "last": "Kruit"
                },
                {
                    "first": "Lev",
                    "initial": "L.",
                    "last": "Demidov"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Thompson"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Bondarenko"
                },
                {
                    "first": "Jaroslaw",
                    "initial": "J.",
                    "last": "Jaroszek"
                },
                {
                    "first": "Susana",
                    "initial": "S.",
                    "last": "Puig"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Cinat"
                },
                {
                    "first": "Axel",
                    "initial": "A.",
                    "last": "Hauschild"
                },
                {
                    "first": "Jelle J.",
                    "initial": "J.J.",
                    "last": "Goeman"
                },
                {
                    "first": "Hans C.",
                    "initial": "H.C.",
                    "last": "van Houwelingen"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "Ulloa-Montoya"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Callegaro"
                },
                {
                    "first": "Benjamin",
                    "initial": "B.",
                    "last": "Dizier"
                },
                {
                    "first": "Bart",
                    "initial": "B.",
                    "last": "Spiessens"
                },
                {
                    "first": "Muriel",
                    "initial": "M.",
                    "last": "Debois"
                },
                {
                    "first": "Vincent G.",
                    "initial": "V.G.",
                    "last": "Brichard"
                },
                {
                    "first": "Jamila",
                    "initial": "J.",
                    "last": "Louahed"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Therasse"
                },
                {
                    "first": "Channa",
                    "initial": "C.",
                    "last": "Debruyne"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Kirkwood"
                }
            ],
            "doi": "10.1016/S1470-2045(18)30254-7",
            "firstpage": "916",
            "issn": "14702045",
            "lastpage": "929",
            "pmid": "29908991",
            "pub_year": 2018,
            "title": "MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial",
            "volume": "19"
        },
        "b0245": {
            "authors": [
                {
                    "first": "Erin Isaacson",
                    "initial": "E.I.",
                    "last": "Wechsler"
                },
                {
                    "first": "Qian",
                    "initial": "Q.",
                    "last": "Wang"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Roberts"
                },
                {
                    "first": "Emilio",
                    "initial": "E.",
                    "last": "Pagliarulo"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Jackson"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Untersperger"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Coleman"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Griffin"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Doorbar"
                }
            ],
            "doi": "10.1128/JVI.07069-11",
            "firstpage": "6358",
            "issn": "0022538X",
            "lastpage": "6364",
            "pmid": "22457518",
            "pub_year": 2012,
            "title": "Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression",
            "volume": "86"
        },
        "b0250": {
            "authors": [
                {
                    "first": "Shreya",
                    "initial": "S.",
                    "last": "Kanodia"
                },
                {
                    "first": "Laura M.",
                    "initial": "L.M.",
                    "last": "Fahey"
                },
                {
                    "first": "W. Martin",
                    "initial": "W.M.",
                    "last": "Kast"
                }
            ],
            "doi": "10.2174/156800907780006869",
            "firstpage": "79",
            "issn": "15680096",
            "lastpage": "89",
            "pmid": "17305480",
            "pub_year": 2007,
            "title": "Mechanisms used by human papillomaviruses to escape the host immune response",
            "volume": "7"
        },
        "b0255": {
            "authors": [
                {
                    "first": "Alina",
                    "initial": "A.",
                    "last": "Steinbach"
                },
                {
                    "first": "Angelika B.",
                    "initial": "A.B.",
                    "last": "Riemer"
                }
            ],
            "doi": "10.1002/ijc.31027",
            "firstpage": "224",
            "issn": "00207136",
            "lastpage": "229",
            "pmid": "28865151",
            "pub_year": 2018,
            "title": "Immune evasion mechanisms of human papillomavirus: An update",
            "volume": "142"
        },
        "b0260": {
            "authors": [
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Barrios"
                },
                {
                    "first": "Esteban",
                    "initial": "E.",
                    "last": "Celis"
                }
            ],
            "doi": "10.1007/s00262-012-1259-8",
            "firstpage": "1307",
            "issn": "03407004",
            "lastpage": "1317",
            "pmid": "22527249",
            "pub_year": 2012,
            "title": "TriVax-HPV: An improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers",
            "volume": "61"
        }
    },
    "body_text": [
        {
            "endOffset": 30087,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "TVGV-1 vaccine adjuvanted by CpG induced significantly higher frequencies of HPV16 E7-specific CD8+ T cells in vaccinated mice compared to TVGV-1 vaccine adjuvanted by GPI-0100.",
            "startOffset": 29910,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 20529,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 20528,
                    "startOffset": 20525
                }
            },
            "secId": "s0005",
            "sentence": "Previous studies have shown that prophylactic vaccination of mice with unadjuvanted PE\u0394III-E7-KDEL3 protein results in generation of E7-specific CD8+ and CD4+ T cell responses and protection against challenge with E7-expressing TC-1 tumor cells [8].",
            "startOffset": 20280,
            "title": "Introduction"
        },
        {
            "endOffset": 45110,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 45109,
                    "startOffset": 45105
                }
            },
            "secId": "s0070",
            "sentence": "In humans, the primary cell targets that express TLR9 are B cells and plasmacytoid dendritic cells (pDCs), while in mice, TLR9-expressing cells also include monocytes, macrophages, and conventional DCs [21].",
            "startOffset": 44903,
            "title": "Discussion"
        },
        {
            "endOffset": 31153,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The GPI-0100 adjuvanted vaccine (TVGV-1-G) induced more IFN\u03b3+/TNF\u03b1+/IL-2+-producing cells proportionally compared to the CpG-adjuvanted vaccine (TVGV-1-C).",
            "startOffset": 30998,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 31601,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "These results indicate that although CpG-adjuvanted TVGV-1 induces a higher frequency of E7-specific T cells, both adjuvants are able to assist the immune response in inducing polyfunctional T cells.",
            "startOffset": 31402,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 17169,
            "parents": [],
            "secId": "s0005",
            "sentence": "Among them are DNA, RNA, viral vectors, bacterial vectors, dendritic cells, peptides and proteins in various iterations and combinations.",
            "startOffset": 17032,
            "title": "Introduction"
        },
        {
            "endOffset": 19393,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 19392,
                    "startOffset": 19385
                },
                "b0085": {
                    "endOffset": 19392,
                    "startOffset": 19385
                }
            },
            "secId": "s0005",
            "sentence": "This generates a mixed Th1/Th2 immune response (biased toward Th1), and stimulates CTL generation through antigen presenting cell (APC) cross-presentation [11,17].",
            "startOffset": 19230,
            "title": "Introduction"
        },
        {
            "endOffset": 22601,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "PE labeled H2-Db-HPV16 E7(49-57) tetramer reagent was acquired from the NIH NIAID Tetramer Core Facility at Emory University (Atlanta, GA).",
            "startOffset": 22462,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 26149,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Five thousand CFSE+ events were collected.",
            "startOffset": 26107,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 28116,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "10).",
            "startOffset": 28112,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 29385,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 29270,
                    "startOffset": 29266
                }
            },
            "secId": "s0055",
            "sentence": "The doses of adjuvant were selected based on previous reported literature directly comparing adjuvant properties of CpG ODN 1826 and GPI-0100 [13], as well as the known MTD in mice for GPI-0100, and the manufacturer recommended dose for CpG (www.invivogen.com).",
            "startOffset": 29124,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 45214,
            "parents": [],
            "refoffsets": {
                "b0210": {
                    "endOffset": 45213,
                    "startOffset": 45209
                }
            },
            "secId": "s0070",
            "sentence": "CpG 1018 is currently FDA approved as an adjuvant in the HEPLISAV-B hepatitis B vaccine (Dynavax) [42].",
            "startOffset": 45111,
            "title": "Discussion"
        },
        {
            "endOffset": 27111,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Following fixation and permeabilization with BD Cytofix/Cytoperm, cells were stained with IFN\u03b3, TNF\u03b1, and IL-2 antibodies or isotype controls.",
            "startOffset": 26969,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 35904,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Although there were no significant differences in survival between the CpG adjuvant group and the GPI-0100 adjuvant group for all treatment cohorts, the day 5 and day 7 therapy cohort results suggest a trend towards the TVGV-1 vaccine adjuvanted with CpG having slightly more therapeutic efficacy than the vaccine adjuvanted with GPI-0100, which is likely related to the higher frequency of antigen-specific T cells that are generated with in vivo lytic capabilities.",
            "startOffset": 35437,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 37590,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There were no significant changes in the overall frequency of CD4+ TIL (Fig. 5d), however, both TVGV-1-C and TVGV-1-G vaccinated groups demonstrated a significant decrease in the frequency of CD4+FoxP3+ Tregs compared to vector control (Fig. 5e).",
            "startOffset": 37344,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 23672,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "After refolding, the protein was further purified by size exclusion chromatography.",
            "startOffset": 23589,
            "title": "TVGV-1 vaccine design and protein synthesis"
        },
        {
            "endOffset": 49180,
            "parents": [],
            "refoffsets": {
                "b0250": {
                    "endOffset": 49179,
                    "startOffset": 49172
                },
                "b0255": {
                    "endOffset": 49179,
                    "startOffset": 49172
                }
            },
            "secId": "s0070",
            "sentence": "Non-optimized codon usage in the papillomavirus genome keeps viral protein expression low in mammalian cells to avoid triggering immune detection [50,51].",
            "startOffset": 49026,
            "title": "Discussion"
        },
        {
            "endOffset": 23779,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The purified protein was formulated in 1 mM histidine, 4% mannitol, 1% sucrose, and 0.005% Tween 80 (v/v).",
            "startOffset": 23673,
            "title": "TVGV-1 vaccine design and protein synthesis"
        },
        {
            "endOffset": 35436,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Importantly, all TVGV-1 vaccinated groups, regardless of adjuvant used or the start day of treatment, showed induction of significant anti-tumor effects resulting in a survival advantage over vector control treated mice.",
            "startOffset": 35216,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 22461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Phorbol 12-myristate 13-acetate (PMA) and ionomycin were purchased from Sigma-Aldrich (St. Louis, MO).",
            "startOffset": 22359,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 19088,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 19087,
                    "startOffset": 19080
                },
                "b0060": {
                    "endOffset": 19087,
                    "startOffset": 19080
                },
                "b0065": {
                    "endOffset": 19087,
                    "startOffset": 19080
                },
                "b0070": {
                    "endOffset": 19087,
                    "startOffset": 19080
                },
                "b0075": {
                    "endOffset": 19087,
                    "startOffset": 19080
                }
            },
            "secId": "s0005",
            "sentence": "GPI-0100 is a non-toxic semi-synthetic dodecylamide saponin derivative of Quillaja saponaria Molina soapbark tree extract that functions as an immunostimulatory adjuvant and has been used with investigational vaccines to improve the immunogenicity of both cancer and infectious disease antigens [11\u201315].",
            "startOffset": 18785,
            "title": "Introduction"
        },
        {
            "endOffset": 42509,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 42508,
                    "startOffset": 42504
                }
            },
            "secId": "s0070",
            "sentence": "Saponin-based adjuvants, such as Quil A, its derivative QS-21, and now the semi-synthetic GPI-0100, are unique in their capacity to induce and enhance Th1 immune responses and generate CTLs against exogenous antigens, an essential characteristic with respect to vaccination against intracellular pathogens or to enhance therapeutic cancer vaccines [34].",
            "startOffset": 42156,
            "title": "Discussion"
        },
        {
            "endOffset": 20686,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 20685,
                    "startOffset": 20682
                }
            },
            "secId": "s0005",
            "sentence": "Furthermore, therapeutic efficacy was demonstrated against early pulmonary metastasis, reducing the number of lung tumor nodules that develop over time [8].",
            "startOffset": 20530,
            "title": "Introduction"
        },
        {
            "endOffset": 28055,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A minimum of 20,000 CD45+ events were acquired on a BD FACSCanto II cytometer.",
            "startOffset": 27977,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 34836,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For mice immunized on days 7, 14 and 21, sixty-percent (6/10) of mice treated with TVGV-1-C vaccine developed progressive tumors.",
            "startOffset": 34707,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 36886,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The presence of CD8+ T cells, CD4+ T cells, regulatory T cells (Tregs), and HPV16 E7-tetramer specific T cells was evaluated by flow cytometry analysis of all CD45+ hematopoietic TIL after tumor tissue dissociation.",
            "startOffset": 36671,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 38588,
            "parents": [],
            "secId": "s0070",
            "sentence": "Antigenic proteins linked to bacterial exotoxins combined with strong immune adjuvants provides a potential platform for increasing immunogenicity and therapeutic efficacy of proteins that alone do not generate a strong enough immune response to show significant anti-tumor activity.",
            "startOffset": 38305,
            "title": "Discussion"
        },
        {
            "endOffset": 17309,
            "parents": [],
            "secId": "s0005",
            "sentence": "These strategies have been supplemented with different adjuvants, heterologous prime-boost regimens, immunostimulants and immunomodulators.",
            "startOffset": 17170,
            "title": "Introduction"
        },
        {
            "endOffset": 21500,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 21499,
                    "startOffset": 21492
                },
                "b0120": {
                    "endOffset": 21499,
                    "startOffset": 21492
                }
            },
            "secId": "s0015",
            "sentence": "C3.43, a progressive subclone of the HPV16-transformed B6 mouse embryo cell line C3, was used for tumor challenge studies [23,24].",
            "startOffset": 21370,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 24968,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Tumor volumes exceeding 1500 mm3 or ulcerated tumors resulted in euthanasia as per animal use guidelines.",
            "startOffset": 24863,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 28400,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "In vitro immunoassay data were analyzed using a one-way analysis of variance (ANOVA) followed by a Tukey\u2019s multiple comparisons test.",
            "startOffset": 28267,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28651,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "P values < 0.05 were considered significant.",
            "startOffset": 28607,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38294,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "These results suggest that even though TVGV-1 therapeutic vaccination is suboptimal in a subset of mice bearing advanced tumors, vaccination with TVGV-1 induces HPV-specific T cells that are capable of migrating to and infiltrating the tumor site, although it is unclear whether they are still functional or have been suppressed by other cells and mechanisms in the local tumor microenvironment.",
            "startOffset": 37899,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 45921,
            "parents": [],
            "refoffsets": {
                "b0225": {
                    "endOffset": 45920,
                    "startOffset": 45916
                }
            },
            "secId": "s0070",
            "sentence": "In a phase III study in non-small-cell lung cancer, CpG 7909 administration (0.2 mg/kg subcutaneous) in combination with chemotherapy, common CpG-related reported adverse events were mild to moderate injection site reactions and flu-like symptoms, which would be expected from CpG\u2019s immune stimulating activity [45].",
            "startOffset": 45605,
            "title": "Discussion"
        },
        {
            "endOffset": 31401,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The presence of E7-specific T cells secreting IFN\u03b3 and IL-2 together in the absence of TNF\u03b1 was infrequent and responding cells were more likely to secrete IFN\u03b3 alone (IFN\u03b3+/TNF\u03b1-/IL-2-) or secrete both IFN\u03b3 and TNF\u03b1 regardless of IL-2 production.",
            "startOffset": 31154,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 36458,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Since tumor regression of more advanced tumors was less frequent than smaller tumors, we next aimed to characterize the tumor TIL populations from mice whose tumors were not cleared in order to potentially gain a mechanistic understanding of why day 7 therapy was suboptimal.",
            "startOffset": 36183,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 50370,
            "parents": [],
            "secId": "s0070",
            "sentence": "Despite the observation that a few mice are not able to clear tumors completely, we do see that the majority of vaccinated mice in both TVGV-1-C and TVGV-1-G vaccinated groups develop very robust anti-tumor immunity capable of clearing pre-established tumors or significantly delaying their growth, resulting in a significant survival advantage.",
            "startOffset": 50025,
            "title": "Discussion"
        },
        {
            "endOffset": 41535,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 41534,
                    "startOffset": 41530
                }
            },
            "secId": "s0070",
            "sentence": "The AS01 adjuvant system is a combination of saponin QS-21 and TLR4 agonist monophosphoryl lipid A (MPLA) with liposomes currently FDA approved for use in the Herpes zoster vaccine (SHINGRIX, GlaxoSmithKline) and approved for use in Europe for the world\u2019s first malaria vaccine (Mosquirix\u2122) [32].",
            "startOffset": 41239,
            "title": "Discussion"
        },
        {
            "endOffset": 43651,
            "parents": [],
            "secId": "s0070",
            "sentence": "Interestingly, our data showed that CpG-adjuvanted TVGV-1 vaccine stimulated an anti-tumor CD8+ T cell response that was similar, but slightly more effectively, than GPI-0100-adjuvanted TVGV-1.",
            "startOffset": 43458,
            "title": "Discussion"
        },
        {
            "endOffset": 23465,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 23464,
                    "startOffset": 23461
                }
            },
            "secId": "s0020",
            "sentence": "The recombinant TVGV-1 (PE-E7-K3) fusion protein was prepared by slightly modifying a method described by Liao et al. [8].",
            "startOffset": 23343,
            "title": "TVGV-1 vaccine design and protein synthesis"
        },
        {
            "endOffset": 35064,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The remaining tumors regressed for overall survival percentages between 30 and 40% (p < 0.0095) (Fig. 4, bottom).",
            "startOffset": 34951,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 23588,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In brief, the protein was expressed in E. coli, isolated from inclusion bodies, purified on DEAE-cellulose, then refolded.",
            "startOffset": 23466,
            "title": "TVGV-1 vaccine design and protein synthesis"
        },
        {
            "endOffset": 41926,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 41925,
                    "startOffset": 41921
                }
            },
            "secId": "s0070",
            "sentence": "Other adjuvants in clinical development but not yet FDA-approved include flagellin (TLR5 agonist), Poly I:C (TLR3 agonist), imidazoquinolines (TLR7/8 agonist), saponins (Quil A, GPI-0100), bacterial toxins and cytokine mixtures [10].",
            "startOffset": 41693,
            "title": "Discussion"
        },
        {
            "endOffset": 43458,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 43457,
                    "startOffset": 43447
                },
                "b0200": {
                    "endOffset": 43457,
                    "startOffset": 43447
                },
                "b0205": {
                    "endOffset": 43457,
                    "startOffset": 43447
                }
            },
            "secId": "s0070",
            "sentence": "In several clinical trials, GPI-0100 adjuvant has been administered to humans without significant toxicity, primarily eliciting mild to moderate injection site reactions [18,40,41].",
            "startOffset": 43277,
            "title": "Discussion"
        },
        {
            "endOffset": 32826,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Vector control immunized mice show very little loss of CFSEhi cell population.",
            "startOffset": 32748,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 42962,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 42961,
                    "startOffset": 42957
                }
            },
            "secId": "s0070",
            "sentence": "In practice, Evans et al. showed that use of the QS-21 adjuvant allows for reduced antigen doses to elicit similar titers of an anti-HIV gp120 subunit vaccine compared to use of no adjuvant, providing a means for dose reduction of immunogen for vaccination [39].",
            "startOffset": 42700,
            "title": "Discussion"
        },
        {
            "endOffset": 42699,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 42698,
                    "startOffset": 42691
                },
                "b0180": {
                    "endOffset": 42698,
                    "startOffset": 42691
                },
                "b0185": {
                    "endOffset": 42698,
                    "startOffset": 42691
                },
                "b0190": {
                    "endOffset": 42698,
                    "startOffset": 42691
                }
            },
            "secId": "s0070",
            "sentence": "Because the undesirable toxic and hemolytic properties of saponin-based adjuvants have been removed, it has opened the door for their safe use for human and veterinary applications [35\u201338].",
            "startOffset": 42510,
            "title": "Discussion"
        },
        {
            "endOffset": 27257,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "10).",
            "startOffset": 27253,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 33373,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In order to investigate the therapeutic efficacy of TVGV-1 vaccination on established tumors, we used the HPV16-induced C3.43 tumor model.",
            "startOffset": 33235,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 24063,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "To prepare TVGV-1-C vaccine with CpG adjuvant, lyophilized TVGV-1 protein was reconstituted to deliver 100 \u00b5g TVGV-1 protein and 50 \u00b5g CpG adjuvant in a volume of 100 \u00b5L per injection.",
            "startOffset": 23879,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 28266,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All statistical analyses were performed using GraphPad Prism version 8.1.0 for Windows (GraphPad Software Inc., San Diego, CA).",
            "startOffset": 28139,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20125,
            "parents": [],
            "secId": "s0005",
            "sentence": "CpG ODNs as vaccine adjuvants improve the function of professional APCs and enhance antigen-specific adaptive immunity.",
            "startOffset": 20006,
            "title": "Introduction"
        },
        {
            "endOffset": 19547,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 19546,
                    "startOffset": 19539
                },
                "b0090": {
                    "endOffset": 19546,
                    "startOffset": 19539
                }
            },
            "secId": "s0005",
            "sentence": "Early phase clinical studies show that GPI-0100 is an effective immune adjuvant with a variety of investigational antigens and is well tolerated [15,18].",
            "startOffset": 19394,
            "title": "Introduction"
        },
        {
            "endOffset": 48022,
            "parents": [],
            "secId": "s0070",
            "sentence": "While we did not test adjuvant combinations in this study, it remains an intriguing proposition to drive optimal immunogenicity with poorly immunogenic protein vaccines.",
            "startOffset": 47853,
            "title": "Discussion"
        },
        {
            "endOffset": 26352,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Peptide specific lysis was calculated with reference to the loss of the CFSEhi target cell population using the following calculation: Percent Specific Lysis = [(%CFSEhi \u2212 %CFSElow)] / (%CFSEhi)] \u00d7 100.",
            "startOffset": 26150,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 30234,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "This could be seen for expression of degranulation marker CD107, as well as IFN\u03b3 production in response to E7 peptide stimulation (Fig. 1a and b).",
            "startOffset": 30088,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 40735,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, the authors also demonstrated that combining the two vaccines (E6 + E7) could produce synergistic effects leading to enhanced survival in tumor-bearing mice.",
            "startOffset": 40569,
            "title": "Discussion"
        },
        {
            "endOffset": 39888,
            "parents": [],
            "secId": "s0070",
            "sentence": "Our results demonstrate that TVGV-1 protein vaccine adjuvanted with either CpG or the GPI-0100 adjuvant induces a high frequency of tumor-infiltrating E7-specific CD8+ T cells.",
            "startOffset": 39712,
            "title": "Discussion"
        },
        {
            "endOffset": 33704,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Mice were implanted with 1 \u00d7 105 C3.43 tumor cells subcutaneously in the rear flank and immunized either 3, 5, or 7 days post-tumor engraftment to test vaccine efficacy with the two different adjuvants with the expectation that more advanced day 7 established tumors might be more difficult to treat than earlier engrafted tumors.",
            "startOffset": 33374,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 46192,
            "parents": [],
            "secId": "s0070",
            "sentence": "Importantly, our data showed that GPI-0100 and CpG-adjuvanted TVGV-1 were both able to induce polyfunctional E7-specific CD8+ T cells characterized by cytokine secretion of IFN\u03b3, TNF\u03b1, and IL-2 and degranulation of the lysosomal marker CD107, a marker for lytic activity.",
            "startOffset": 45921,
            "title": "Discussion"
        },
        {
            "endOffset": 21118,
            "parents": [],
            "secId": "s0005",
            "sentence": "In this study, we evaluated and compared the immunogenicity and adjuvant activity of GPI-0100 or CpG with TVGV-1 protein therapeutic vaccination in a preclinical mouse model for HPV16-induced cancer.",
            "startOffset": 20919,
            "title": "Introduction"
        },
        {
            "endOffset": 32747,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Strong positive correlation was observed between in vivo lytic activity and the percentage of degranulating CD107+ CD8+ T cells (R2 = 0.6931, Fig. 2b).",
            "startOffset": 32596,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 26968,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "CD11b and B220/CD45R staining was used to exclude non-T cells from analysis.",
            "startOffset": 26892,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 16695,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although preventive HPV vaccines have been available for the past decade, prophylactic vaccination to induce protective antibody responses does not address the immediate need for a therapeutic vaccine that targets HPV-associated diseases in people already infected and which requires induction of a strong anti-tumor T cell-mediated immune response.",
            "startOffset": 16346,
            "title": "Introduction"
        },
        {
            "endOffset": 27851,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For intracellular FoxP3 staining, cells were permeabilized overnight at 4 \u00b0C using FoxP3 intracellular stain fixing and permeabilization buffer (ThermoFisher Scientific).",
            "startOffset": 27681,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 29909,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Splenocytes were tested for the presence of antigen-specific CD8+ T cells using in vitro stimulation with the immunodominant HPV16 E7(49-57) peptide and flow cytometry to analyze CD107a/CD107b (LAMP-1/LAMP-2) expression as a marker for cytolytic degranulation and the presence of secreted effector cytokines IFN\u03b3, TNF\u03b1, and IL-2 by intracellular cytokine staining.",
            "startOffset": 29545,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 24724,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "At the indicated day post challenge, mice were administered 3 doses, one week apart, of 100 \u00b5g TVGV-1-C, TVGV-1-G, or vector control.",
            "startOffset": 24591,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 34062,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For mice immunized on days 3, 10 and 17, both CpG-adjuvanted and GPI-0100-adjuvanted TVGV-1 vaccine resulting in 100% tumor regression within 18 days, whereas all control treated mice developed progressive tumors over time (p < 0.0001) (Fig. 3, top panel).",
            "startOffset": 33806,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 48404,
            "parents": [],
            "secId": "s0070",
            "sentence": "Similarly, fusion of only the PE\u0394III domain to E7 was suboptimal for inducing a T cell response.",
            "startOffset": 48308,
            "title": "Discussion"
        },
        {
            "endOffset": 17031,
            "parents": [],
            "secId": "s0005",
            "sentence": "There have been numerous and extensive studies that have generated promising vaccine candidates tested in clinical trials for HPV-associated diseases.",
            "startOffset": 16881,
            "title": "Introduction"
        },
        {
            "endOffset": 47585,
            "parents": [],
            "secId": "s0070",
            "sentence": "Their results revealed five adjuvant combinations that showed superiority in augmenting antibody responses to these antigens with a strong correlation to a Th1 response, one combination in particular being QS-21 + CpG ODN 1826.",
            "startOffset": 47358,
            "title": "Discussion"
        },
        {
            "endOffset": 30721,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The hallmark cytokine produced by antigen-specific CD8+ T cells is IFN\u03b3; however, it is believed that T cells that secrete more than one effector cytokine are functionally superior in their anti-tumor and anti-viral effects.",
            "startOffset": 30497,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 27307,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Gating was set based on isotype control staining.",
            "startOffset": 27258,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 37343,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Notably, of the infiltrating CD8+ T cells, a significant percentage were E7(49-57)-tetramer positive (Fig. 5c), whereas no significant tetramer positive cells were observed in the vector control mice.",
            "startOffset": 37143,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 24376,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For immunogenicity studies, mice (5/group) were immunized subcutaneously (s.c.) at the base of the neck with 100 \u00b5g of TVGV-1-C, TVGV-1-G, or vector control on days 0, 7, and 14.",
            "startOffset": 24198,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 34950,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Seventy-percent (7/10) of mice treated with TVGV-1-G vaccine developed progressive tumors (Fig. 3, bottom panel).",
            "startOffset": 34837,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 34498,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For mice immunized on days 5, 12, and 19, the two groups immunized with either TVGV-1-C and TVGV-1-G showed 60% tumor regression while 4/10 mice developed progressing tumors (Fig. 3, middle panel).",
            "startOffset": 34301,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 37142,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In tumor-bearing mice that received the TVGV-1-C vaccine, we observed a significantly greater increase in the overall percentage of CD8+ TIL and in the HPV16 E7-specific CD8+ TIL population compared to mice that received the TVGV-1-G vaccine (Fig. 5a, b).",
            "startOffset": 36887,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 28606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Spearman rank-order correlation was used to analyze the association of in vivo lytic activity and CD107 degranulation in antigen-specific T cells.",
            "startOffset": 28460,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34300,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Several mice developed small but measurable tumors in the vaccine groups, which subsequently regressed over the course of the vaccine regimen, resulting in 100% survival of all mice treated with TVGV-1 with either adjuvant (Fig. 4, top).",
            "startOffset": 34063,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 36670,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Progressively growing tumors were harvested between days 30\u201360 post challenge, depending on their growth rate.",
            "startOffset": 36560,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 51061,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, vaccination with the TVGV-1 construct in combination with adjuvant represents a viable therapeutic vaccine for the treatment of HPV-associated tumors.",
            "startOffset": 50900,
            "title": "Discussion"
        },
        {
            "endOffset": 38809,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 38808,
                    "startOffset": 38804
                }
            },
            "secId": "s0070",
            "sentence": "The P. aeruginosa exotoxin A domains I and II have unique cell binding and translocation functions that allow them to transport covalently linked proteins into the cytosol of professional APCs when injected in vivo [25].",
            "startOffset": 38589,
            "title": "Discussion"
        },
        {
            "endOffset": 44282,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 44281,
                    "startOffset": 44277
                }
            },
            "secId": "s0070",
            "sentence": "While both GPI-0100 and CpG trigger immune responses characterized by strong Th1, CTL, antibody responses, and activation of NK cells, they do so through different cellular interactions [10].",
            "startOffset": 44091,
            "title": "Discussion"
        },
        {
            "endOffset": 49468,
            "parents": [],
            "refoffsets": {
                "b0260": {
                    "endOffset": 49467,
                    "startOffset": 49463
                }
            },
            "secId": "s0070",
            "sentence": "Indeed, E7-specific CD8+ T cells isolated from TriVax-HPV vaccinated mice were 50% less activated by C3.43 tumor cell stimulation compared to TC-1 tumor cells, some of which was partially rescued by IFN\u03b3-mediated upregulation of MHC class I expression on the surface of C3.43 cells [52].",
            "startOffset": 49181,
            "title": "Discussion"
        },
        {
            "endOffset": 49733,
            "parents": [],
            "secId": "s0070",
            "sentence": "These data indirectly suggest that C3.43 cells express less E7 peptide MHC complexes on the surface compared to TC-1 cells, and therefore may require a more robust immune response to see similar tumor regression efficacy in vivo with any given therapeutic vaccine.",
            "startOffset": 49469,
            "title": "Discussion"
        },
        {
            "endOffset": 28459,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Survival data were analyzed by a log rank Mantel-Cox test.",
            "startOffset": 28401,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 21369,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Pathogen-free 7 week old C57BL/6 female mice were purchased from Taconic Biosciences (Oxnard, CA) and were acclimated to the new housing environment for at least one week prior to use.",
            "startOffset": 21185,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 32595,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Mice immunized with TVGV-1-C demonstrated significantly higher in vivo lysis compared to mice immunized with TVGV-1-G, which was consistent with the frequency of CD107+ degranulating lytic T cells (Fig. 1a).",
            "startOffset": 32388,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 32192,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "After 20 h, loss of the E7-labeled CFSEhi population compared to control was evaluated by flow cytometry and used as a measure of the in vivo lysis capacity of vaccine-induced HPV-specific T cells.",
            "startOffset": 31995,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 25760,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Control peptide-pulsed cells were labeled with 0.66 \u00b5M CFSE.",
            "startOffset": 25700,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 39138,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 39137,
                    "startOffset": 39134
                }
            },
            "secId": "s0070",
            "sentence": "The KDEL ER retention domain of the TVGV-1 fusion protein drives the E7 antigen into the cross presentation pathway for MHC class I, improving antigen-specific immune responses [8].",
            "startOffset": 38957,
            "title": "Discussion"
        },
        {
            "endOffset": 26891,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "After incubation, cells were washed and stained with the Zombie Aqua viability dye and antibodies against CD3, CD4, and CD8.",
            "startOffset": 26767,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 30833,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, responding T cells from vaccinated mice were analyzed for simultaneous effector cytokine production.",
            "startOffset": 30722,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 50024,
            "parents": [],
            "secId": "s0070",
            "sentence": "This is reflected in our study when we compare the overall tumor burden and survival of day 3 therapeutically treated mice to day 7 treated mice.",
            "startOffset": 49879,
            "title": "Discussion"
        },
        {
            "endOffset": 27196,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Data acquisition was performed on a BD FACSCanto II flow cytometer (BD Biosciences).",
            "startOffset": 27112,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 32937,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Background loss of CFSEhi cells may be related to spontaneous cell death due to the high amount of CFSE label.",
            "startOffset": 32827,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 36182,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In addition to induction of systemic cellular immune responses, an effective therapeutic vaccine should trigger migration of antigen-specific CD8+ T cells to the tumor site.",
            "startOffset": 36009,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 22830,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "GPI-0100 was licensed by Hawaii Biotech Inc. (Honolulu, HI) and provided for study investigations by TheVax Genetics Vaccine Co. Ltd. (Taiwan, R.O.C.).",
            "startOffset": 22679,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 25953,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Twenty hours after injection into vaccinated mice, splenocytes were isolated and analyzed by flow cytometry.",
            "startOffset": 25845,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 48307,
            "parents": [],
            "secId": "s0070",
            "sentence": "Liao et al. demonstrated that delivery of the E7 protein alone does not induce any anti-tumor response.",
            "startOffset": 48204,
            "title": "Discussion"
        },
        {
            "endOffset": 49878,
            "parents": [],
            "secId": "s0070",
            "sentence": "Tumor burden also plays a role in determining vaccine and adjuvant efficacy, since more established tumors are generally more difficult to treat.",
            "startOffset": 49733,
            "title": "Discussion"
        },
        {
            "endOffset": 39711,
            "parents": [],
            "secId": "s0070",
            "sentence": "The goal of this study was to investigate the effect of combining TVGV-1 (PE\u0394III-E7-KDEL3) with two different immunostimulatory adjuvants and to compare immunogenicity and anti-tumor activity of the resulting immune response in the established HPV16-induced C3.43 tumor model.",
            "startOffset": 39435,
            "title": "Discussion"
        },
        {
            "endOffset": 44902,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 44901,
                    "startOffset": 44897
                }
            },
            "secId": "s0070",
            "sentence": "In contrast, CpG ODNs target TLR9, a receptor for conserved pathogen-associated molecular patterns (PAMPS), which when engaged causes downstream signaling events that lead to activation of NF\u03baB and IRF3, followed by transcriptional activation and expression of proinflammatory cytokines, including type I interferons [21].",
            "startOffset": 44580,
            "title": "Discussion"
        },
        {
            "endOffset": 28111,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Flow data were analyzed utilizing FlowJo software (ver.",
            "startOffset": 28056,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 44090,
            "parents": [],
            "secId": "s0070",
            "sentence": "Adjuvants can have very profound effects on the nature of immune responses with some adjuvants favoring humoral and Th2-biased responses, and others favoring Th1 and CTL production.",
            "startOffset": 43909,
            "title": "Discussion"
        },
        {
            "endOffset": 51142,
            "parents": [],
            "secId": "s0075",
            "sentence": "The author declares that there is no conflict of interest.",
            "startOffset": 51084,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 19229,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 19228,
                    "startOffset": 19221
                },
                "b0080": {
                    "endOffset": 19228,
                    "startOffset": 19221
                }
            },
            "secId": "s0005",
            "sentence": "GPI-0100 also facilitates delivery of exogenous protein antigens directly to the cell cytosol for processing by endogenous pathways [12,16].",
            "startOffset": 19089,
            "title": "Introduction"
        },
        {
            "endOffset": 25177,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Mice were observed for the duration of each experiment for signs of adjuvant toxicity or pain, including behavioral changes, loss of appetite, dehydration, weight loss, piloerection, and local skin reactions.",
            "startOffset": 24969,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 36559,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Mice (15/group) were challenged with 1 \u00d7 105 C3.43 tumor cells and vaccinated on days 7, 14, and 21.",
            "startOffset": 36459,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 38956,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 38955,
                    "startOffset": 38949
                },
                "b0130": {
                    "endOffset": 38955,
                    "startOffset": 38949
                }
            },
            "secId": "s0070",
            "sentence": "Deletion of the ADP-ribosylating catalytic domain III renders the exotoxin non-cytopathic to cells and greatly reduces associated toxicity [9,26].",
            "startOffset": 38810,
            "title": "Discussion"
        },
        {
            "endOffset": 27680,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Isolated TILs were stained with Zombie Aqua to exclude dead cells, then stained for surface antigens.",
            "startOffset": 27579,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 24590,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For therapeutic vaccine efficacy studies, mice (10\u201315/group) were challenged s.c. on the flank with 1 \u00d7 105 C3.43 tumor cells in 100 \u00b5L Hanks Balanced Salt Solution on day 0.",
            "startOffset": 24416,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 27252,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Flow data were analyzed utilizing FlowJo software (ver.",
            "startOffset": 27197,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 29544,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Immunogenicity was evaluated in vitro 10 days after the last vaccination.",
            "startOffset": 29471,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 43908,
            "parents": [],
            "secId": "s0070",
            "sentence": "Differences in the quantity and quality of observed anti-E7 immune responses in this study between the two vaccine formulations are presumed to be related to the different mechanism of action of each adjuvant since the immunogen was the same in each group.",
            "startOffset": 43652,
            "title": "Discussion"
        },
        {
            "endOffset": 39434,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 39433,
                    "startOffset": 39426
                },
                "b0140": {
                    "endOffset": 39433,
                    "startOffset": 39426
                },
                "b0145": {
                    "endOffset": 39433,
                    "startOffset": 39426
                }
            },
            "secId": "s0070",
            "sentence": "Prior studies have shown the importance of directing antigen into the cytosol and ER for generation of anti-HPV16 E6 and/or E7 tumor immunity using various strategies, including the use of heat shock protein fusions, calreticulin, and Bordatella pertussis adenylate cyclase, for example [27\u201329].",
            "startOffset": 39139,
            "title": "Discussion"
        },
        {
            "endOffset": 30997,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "As a proportion of the responding CD8+ T cell population, more than 60% of effector T cells produced both IFN\u03b3 and TNF\u03b1 in both TVGV-1 vaccinated groups (Fig. 1e).",
            "startOffset": 30834,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 27578,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Tumor tissue was isolated from mice (12\u201314/group) and processed into single cell suspensions using a mouse tumor dissociation kit with the GentleMACS system (Miltenyi, Auburn, CA) according to manufacturer\u2019s instructions.",
            "startOffset": 27357,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 20280,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 20279,
                    "startOffset": 20275
                }
            },
            "secId": "s0005",
            "sentence": "Importantly, CpG ODNs have a good safety profile in human clinical trials and show efficacy in increasing immunogenicity of co-administered vaccines [21].",
            "startOffset": 20126,
            "title": "Introduction"
        },
        {
            "endOffset": 27976,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The following day, cells were washed in permeabilization buffer and stained with FoxP3 antibody or isotype control antibody.",
            "startOffset": 27852,
            "title": "Tumor infiltrating lymphocyte (TIL) phenotyping"
        },
        {
            "endOffset": 34706,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Although tumors in TVGV-1-C treated mice grew at a slower rate compared to TVGV-1-G vaccinated mice, overall long term survival and tumor-free percentage of both groups was 60% (p < 0.0001) (Fig. 4, middle).",
            "startOffset": 34499,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 17885,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 17884,
                    "startOffset": 17881
                }
            },
            "secId": "s0005",
            "sentence": "The Pseudomonas Exotoxin-HPV16 E7-KDEL3 fusion protein (PE\u0394III-E7-KDEL3; also termed TVGV-1) is a recombinant protein composed of 3 fused subunits: the translocation domains I and II of Pseudomonas aeruginosa exotoxin A at the N-terminus, full length HPV16 E7 protein in the middle and a triple KDEL endoplasmic reticulum (ER) retention signal at the C-terminus [8].",
            "startOffset": 17519,
            "title": "Introduction"
        },
        {
            "endOffset": 15844,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 15843,
                    "startOffset": 15840
                }
            },
            "secId": "s0005",
            "sentence": "Persistent infection with high-risk human papillomaviruses (HPVs) are the causative agent in virtually all cervical cancer cases, a significant number of other anogenital cancers, and a subset of oropharyngeal cancers [1].",
            "startOffset": 15622,
            "title": "Introduction"
        },
        {
            "endOffset": 26766,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Ten days after the last vaccination, splenocytes were isolated from mice (5/group) and stimulated in vitro with 5 \u00b5g/mL HPV16 E7(49-57) peptide or control peptide in the presence of 10 \u00b5g/mL GolgiPlug (brefeldin A), 10 \u00b5g/mL GolgiStop (monensin) and antibodies to CD107a and CD107b (BD Biosciences) for 6 h at 37 \u00b0C, 5% CO2 in a humidified incubator.",
            "startOffset": 26416,
            "title": "CD107 degranulation assay and intracellular cytokine staining"
        },
        {
            "endOffset": 22358,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Rat IgG2a FITC, rat IgG2b PE, rat IgG PerCP-Cy5.5, rat IgG1, CD107a FITC, CD107b FITC, IL-2 PE, IFN\u03b3 PerCp-Cy5.5, TNF\u03b1 PE-Cy7, Fc Block, BD GolgiPlug, and BD Cytofix/Cytoperm were purchased from BD Biosciences (San Jose, CA).",
            "startOffset": 22133,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 42155,
            "parents": [],
            "secId": "s0070",
            "sentence": "Although imiquimod (TLR7/8 agonist, Aldara\u2122) is not approved as a vaccine adjuvant, it is approved by the FDA as a stand-alone topical treatment for actinic keratosis, superficial basal cell carcinoma and external genital warts.",
            "startOffset": 41927,
            "title": "Discussion"
        },
        {
            "endOffset": 30375,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "TVGV-1-C vaccination resulted in a significant increase in E7-specific TNF\u03b1-secreting CD8+ T cells compared to the vector control (Fig. 1c).",
            "startOffset": 30235,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 41692,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 41691,
                    "startOffset": 41687
                }
            },
            "secId": "s0070",
            "sentence": "AS04 combines MPLA and Alum to induce a Th1-biased immune response and is currently used in a HBV vaccine and HPV vaccine developed by GlaxoSmithKline [33].",
            "startOffset": 41536,
            "title": "Discussion"
        },
        {
            "endOffset": 31807,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, we subsequently tested the in vivo cytotoxic activity of T cells induced after vaccination.",
            "startOffset": 31705,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 48203,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 48202,
                    "startOffset": 48199
                }
            },
            "secId": "s0070",
            "sentence": "Previous studies testing the PE\u0394III-E7-KDEL3 vaccine in the TC-1 HPV16-transformed tumor model has shown vaccine efficacy in the preventative setting in the absence of adjuvant [8].",
            "startOffset": 48022,
            "title": "Discussion"
        },
        {
            "endOffset": 17519,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 17517,
                    "startOffset": 17514
                }
            },
            "secId": "s0005",
            "sentence": "Despite this enormous effort, there are currently no approved therapeutic vaccines for HPV-induced cancers or precancerous lesions, though several candidates are currently in clinical trials (reviewed in [7]).",
            "startOffset": 17310,
            "title": "Introduction"
        },
        {
            "endOffset": 22026,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The following anti-mouse antibodies, isotype controls and reagents were purchased from Biolegend (San Diego, CA): CD3 FITC, CD3 APC-Cy7, CD4 PE, CD4 BV421, CD8a PerCP-Cy5.5, CD8 APC, CD45 APC-Cy7, CD45R/B220 BV510, CD11b BV510, rat IgG2a FITC, rat IgG2b PE, rat IgG1 PE-Cy5, rat IgG2b APC, rat IgG2b PE-Cy7, FluoroFix buffer and Zombie Aqua.",
            "startOffset": 21685,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 25844,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "After extensive washing in PBS, cells were mixed in a 1:1 ratio prior to injection.",
            "startOffset": 25761,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 46916,
            "parents": [],
            "secId": "s0070",
            "sentence": "The differences in the induced immune responses might indeed be related to stronger activation of the proinflammatory response through CpG-induced TLR9 activation, as we observed higher numbers of E7-specific T cells, greater anti-tumor efficacy, and even within mice whose tumors were not controlled, there were greater frequencies of E7-specific TIL within the CD8+ TIL population.",
            "startOffset": 46533,
            "title": "Discussion"
        },
        {
            "endOffset": 24862,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Tumor growth was measured two times per week with manual calipers by measuring tumor length, width, and depth to generate a tumor volume.",
            "startOffset": 24725,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 50899,
            "parents": [],
            "secId": "s0070",
            "sentence": "In summary, targeting the MHC class I cross-presentation pathway using the translocating properties of bacterial exotoxin in an HPV16 E7 KDEL fusion protein adjuvanted with either CpG or GPI-0100 results in a strongly immunogenic antigen-specific T cell profile that demonstrates therapeutic efficacy in a very aggressive pre-clinical HPV-driven tumor model in which expression of the E7 antigen is physiologically expressed under the natural viral promoter, similar to that which would be found in virally-induced human cancers.",
            "startOffset": 50370,
            "title": "Discussion"
        },
        {
            "endOffset": 18660,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 18659,
                    "startOffset": 18655
                }
            },
            "secId": "s0005",
            "sentence": "Vaccine adjuvants, functionally defined as either vehicles for optimal antigen delivery or direct immunostimulants, are compounds that can enhance the magnitude, breadth, quality and longevity of induced antigen-specific immune responses and are frequently used to augment therapeutic vaccine strategies [10].",
            "startOffset": 18351,
            "title": "Introduction"
        },
        {
            "endOffset": 40568,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 40567,
                    "startOffset": 40563
                }
            },
            "secId": "s0070",
            "sentence": "Indeed, Chen et al. reported that vaccination with a PE\u0394III-E7-KDEL3 monovalent fusion protein could elicit better immune and anti-tumor immune responses compared to a PE\u0394III-E6-KDEL3 monovalent fusion protein in the TC-1 tumor model [30].",
            "startOffset": 40329,
            "title": "Discussion"
        },
        {
            "endOffset": 48704,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 48703,
                    "startOffset": 48700
                }
            },
            "secId": "s0070",
            "sentence": "These responses were sufficient in quantity to reduce the number of pulmonary metastasis of TC-1 cells when mice were vaccinated two days after tumor challenge [8].",
            "startOffset": 48540,
            "title": "Discussion"
        },
        {
            "endOffset": 23844,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The protein was then lyophilized and stored at 2\u20138 \u00b0C until use.",
            "startOffset": 23780,
            "title": "TVGV-1 vaccine design and protein synthesis"
        },
        {
            "endOffset": 31704,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The CD107 mobilization-degranulation assay indicated that TVGV-1 vaccinated mice could be highly lytic.",
            "startOffset": 31601,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 30497,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "IL-2 expression in vaccinated mice was low and not significantly increased when compared to the vector control (Fig. 1d).",
            "startOffset": 30376,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 40119,
            "parents": [],
            "secId": "s0070",
            "sentence": "Furthermore, both adjuvants are able to assist the immune response in inducing polyfunctional cytokine-secreting lytic T cells that show substantial therapeutic efficacy against well-established C3.43 tumors as a proof of concept.",
            "startOffset": 39889,
            "title": "Discussion"
        },
        {
            "endOffset": 45342,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 45341,
                    "startOffset": 45334
                },
                "b0215": {
                    "endOffset": 45341,
                    "startOffset": 45334
                }
            },
            "secId": "s0070",
            "sentence": "Importantly, a number of phase I-III clinical trials support the therapeutic potential of CpG ODNs for cancer vaccines [10,43].",
            "startOffset": 45215,
            "title": "Discussion"
        },
        {
            "endOffset": 24415,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Assays were performed on day 21 or 25.",
            "startOffset": 24377,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 18116,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 18115,
                    "startOffset": 18112
                }
            },
            "secId": "s0005",
            "sentence": "Cell binding and cytoplasmic translocation features of bacterial exotoxins results in retrograde delivery of foreign proteins to cytosolic compartments, enhancing MHC class I presentation of exogenous antigen to T lymphocytes [9].",
            "startOffset": 17886,
            "title": "Introduction"
        },
        {
            "endOffset": 25249,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "No toxicities were noted in either the GPI-0100 or CpG vaccinated mice.",
            "startOffset": 25178,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 47133,
            "parents": [],
            "secId": "s0070",
            "sentence": "Understandably, combining adjuvants has been proposed as a strategy to improve desired immune responses compared to single-agent adjuvant in order to derive benefit from the differential immunostimulatory properties.",
            "startOffset": 46917,
            "title": "Discussion"
        },
        {
            "endOffset": 23013,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The H2-Db-binding peptide, HPV16 E7(49\u201357) RAHYNIVTF, was synthesized at the University of Chicago (Chicago, IL) and purified by reverse phase high-performance liquid chromatography.",
            "startOffset": 22831,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 22132,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "CD25 PerCP-Cy5.5, FoxP3 PE-Cy7, and Rat IgG1 PerCP-Cy5.5 were purchased from eBioscience (San Diego, CA).",
            "startOffset": 22027,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 29470,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "These adjuvant doses result in optimal immunogenicity of the TVGV-1 protein vaccine.",
            "startOffset": 29386,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 35215,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "As was expected, earlier vaccination results in more significant tumor therapy and prolonged survival compared to treatment at advanced growth stages.",
            "startOffset": 35065,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 41238,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 41237,
                    "startOffset": 41233
                }
            },
            "secId": "s0070",
            "sentence": "Many adjuvants have been tested in human clinical trials, however the only ones approved for human use are aluminum salts (Alum), oil-in-water emulsions (MF59, AS03), liposome-based virosomes, and various combinations of immunostimulants [31].",
            "startOffset": 40995,
            "title": "Discussion"
        },
        {
            "endOffset": 16345,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 16344,
                    "startOffset": 16341
                }
            },
            "secId": "s0005",
            "sentence": "The viral oncoproteins E6 and E7 are the preferred viral protein targets for development of therapeutic vaccines for HPV-induced malignancies due to their role in tumorigenesis and maintenance of transformed cells [5].",
            "startOffset": 16127,
            "title": "Introduction"
        },
        {
            "endOffset": 18784,
            "parents": [],
            "secId": "s0005",
            "sentence": "Examples of immunostimulatory adjuvants are toll-like receptor (TLR) ligands, cytokines, saponins, and bacterial exotoxins.",
            "startOffset": 18661,
            "title": "Introduction"
        },
        {
            "endOffset": 44579,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 44578,
                    "startOffset": 44574
                }
            },
            "secId": "s0070",
            "sentence": "GPI-0100, like other saponins, targets antigen processing through enhanced antigen uptake by APC via endocytosis, as well as providing direct stimulation of T cells through a lipophilic acyl group moiety, but which has been rendered non-toxic in GPI-0100 compared to its natural counterpart [12].",
            "startOffset": 44283,
            "title": "Discussion"
        },
        {
            "endOffset": 31994,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Differentially-labeled CFSEhi and CFSElow target cells labeled with E7 peptide or an irrelevant peptide, respectively, were injected into vaccinated mice 7 days after the last injection.",
            "startOffset": 31808,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 16126,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16125,
                    "startOffset": 16120
                },
                "b0015": {
                    "endOffset": 16125,
                    "startOffset": 16120
                },
                "b0020": {
                    "endOffset": 16125,
                    "startOffset": 16120
                }
            },
            "secId": "s0005",
            "sentence": "HPV16 is the most carcinogenic genotype relative to other high risk HPVs, being found in 60% of invasive cervical cancer cases and the predominant genotype also found in vulvar, vaginal, anal, penile lesions, and almost all HPV-associated oropharyngeal head and neck cancers [2\u20134].",
            "startOffset": 15845,
            "title": "Introduction"
        },
        {
            "endOffset": 16880,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 16878,
                    "startOffset": 16875
                }
            },
            "secId": "s0005",
            "sentence": "As such, vaccination strategies targeting HPV16 E6 and/or E7 to induce cytotoxic T lymphocytes (CTLs) are the focal point for current therapeutic vaccine development (reviewed in [6]).",
            "startOffset": 16696,
            "title": "Introduction"
        },
        {
            "endOffset": 46402,
            "parents": [],
            "secId": "s0070",
            "sentence": "While CpG-immunized mice showed twice the level of CD107 degranulation as GPI-0100-immunized mice by intracellular cytokine staining, in vivo CTL lysis differences, although significant, were not as prominent.",
            "startOffset": 46193,
            "title": "Discussion"
        },
        {
            "endOffset": 20918,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, therapeutic activity of this fusion protein against well-established subcutaneous solid tumors has not been investigated nor has this protein been combined with adjuvants that may further enhance cellular immune responses.",
            "startOffset": 20687,
            "title": "Introduction"
        },
        {
            "endOffset": 33805,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Mice were boosted two additional times one week apart for a total of 3 doses of vaccine per regimen.",
            "startOffset": 33705,
            "title": "Therapeutic vaccination of tumor-bearing mice with TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces tumor regression and increases overall survival"
        },
        {
            "endOffset": 29123,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "To assess the effect of using either CpG adjuvant or GPI-0100 adjuvant on the immunogenicity of the TVGV-1 (PE\u0394III-E7-KDEL3) protein vaccine, we immunized mice three times, one week apart, with 100 \u00b5g TVGV-1 formulated with either 50 \u00b5g CpG adjuvant (TVGV-1-C) or 100 \u00b5g GPI-0100 (TVGV-1-G) or vector control with no adjuvant.",
            "startOffset": 28797,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 32387,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Both TVGV-1-C and TVGV-1-G vaccinated groups demonstrated significant in vivo lysis compared to the vector control group which shown minimal in vivo lysis of target cells (p < 0.0001) (Fig. 2a).",
            "startOffset": 32193,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 49025,
            "parents": [],
            "refoffsets": {
                "b0245": {
                    "endOffset": 49024,
                    "startOffset": 49020
                }
            },
            "secId": "s0070",
            "sentence": "Importantly, expression of E7 protein is under physiologic regulation and is likely similar to the low levels of expression found in HPV16-infected human tissue [49].",
            "startOffset": 48859,
            "title": "Discussion"
        },
        {
            "endOffset": 21684,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "C3.43 cells were grown and expanded in vitro with IMDM medium supplemented with 10% fetal bovine serum (FBS; Gemini, Sacramento, CA), 50 uM 2-mercaptoethanol, and 50 \u00b5g/mL gentamicin.",
            "startOffset": 21501,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 33072,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Overall, TVGV-1-C immunization resulted in the greatest differentiation of phenotypically desirable polyfunctional, cytotoxic T cells.",
            "startOffset": 32938,
            "title": "TVGV-1 vaccine adjuvanted with either CpG or GPI-0100 induces polyfunctional HPV16 E7-specific CD8+ T cells with in vivo lytic activity"
        },
        {
            "endOffset": 22678,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "CpG oligonucleotide (ODN-1826) was purchased from InvivoGen (San Diego, CA).",
            "startOffset": 22602,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 45604,
            "parents": [],
            "refoffsets": {
                "b0220": {
                    "endOffset": 45603,
                    "startOffset": 45599
                }
            },
            "secId": "s0070",
            "sentence": "In a phase I study in 41 patients with chronic lymphocytic leukemia, a single intravenous dose of CpG 7909 was well tolerated with no significant toxicity up to 1.05 mg/kg, and a maximum tolerated dose of 0.45 mg/kg was found when delivered subcutaneously [44].",
            "startOffset": 45343,
            "title": "Discussion"
        },
        {
            "endOffset": 26106,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Percentage of remaining CFSEhi and CFSElow cells were analyzed using FlowJo flow cytometry analysis software (Becton, Dickinson & Company, Ashland, OR).",
            "startOffset": 25954,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 19837,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 19836,
                    "startOffset": 19829
                },
                "b0100": {
                    "endOffset": 19836,
                    "startOffset": 19829
                }
            },
            "secId": "s0005",
            "sentence": "CpG synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger immune cells that express TLR9, which include plasmacytoid dendritic cells (pDCs) and B cells, and stimulates immune responses characterized by the production of Th1 and proinflammatory cytokines [19,20].",
            "startOffset": 19547,
            "title": "Introduction"
        },
        {
            "endOffset": 25522,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Seven days after the last vaccination, mice (5/group) were injected intravenously under inhalation anesthesia with 10 \u00d7 106 CFSE-labeled na\u00efve splenocytes that were pulsed with 0.5 \u00b5g/mL HPV16 E7(49-57) peptide or an irrelevant control peptide.",
            "startOffset": 25278,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 25699,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "E7-pulsed target cells were labeled with 10 \u00b5M CFSE (Vybrant Carboxyfluorescein diacetate succinimidyl ester (CFDA SE) Cell Tracer Kit, Thermo Fisher Scientific, Carlsbad, CA).",
            "startOffset": 25523,
            "title": "In vivo cytolytic activity"
        },
        {
            "endOffset": 40995,
            "parents": [],
            "secId": "s0070",
            "sentence": "Because both E6 and E7 play important roles in HPV-associated carcinogenesis in humans, a therapeutic vaccine strategy based on this reported platform would benefit from inclusion of both viral oncogenes as target tumor antigens if being developed clinically.",
            "startOffset": 40736,
            "title": "Discussion"
        },
        {
            "endOffset": 18350,
            "parents": [],
            "secId": "s0005",
            "sentence": "While PE\u0394III-E7-KDEL3 has been designed in an attempt to generate a robust response on its own, the development of weak cellular and humoral immune responses is common following protein-based vaccination in the absence of an adjuvant.",
            "startOffset": 18116,
            "title": "Introduction"
        },
        {
            "endOffset": 40328,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 40327,
                    "startOffset": 40323
                }
            },
            "secId": "s0070",
            "sentence": "The E6 antigen in this mouse model and in others (TC-1) is less important for tumor rejection, since E7-derived peptides are more immunogenic in C57BL/6 mice based on H2-Kb and H2-Db MHC peptide binding [23].",
            "startOffset": 40120,
            "title": "Discussion"
        },
        {
            "endOffset": 47357,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 47356,
                    "startOffset": 47352
                }
            },
            "secId": "s0070",
            "sentence": "For example, the saponin-based adjuvant QS-21 was tested in twelve different adjuvant combinations by Kim et al. to determine which combination induced a more potent immune response to two cancer antigens GD3 and MUC1 [13].",
            "startOffset": 47134,
            "title": "Discussion"
        },
        {
            "endOffset": 47852,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 47851,
                    "startOffset": 47841
                },
                "b0230": {
                    "endOffset": 47851,
                    "startOffset": 47841
                },
                "b0235": {
                    "endOffset": 47851,
                    "startOffset": 47841
                },
                "b0240": {
                    "endOffset": 47851,
                    "startOffset": 47841
                }
            },
            "secId": "s0070",
            "sentence": "Similarly, the AS15 adjuvant system (MPLA, QS-21, and CpG 7909; GlaxoSmithKline) was chosen for its immunostimulatory activity to support clinical development of melanoma immunotherapeutic vaccines with human safety results being within acceptable limits [33,46\u201348].",
            "startOffset": 47586,
            "title": "Discussion"
        },
        {
            "endOffset": 20005,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 20004,
                    "startOffset": 19997
                },
                "b0110": {
                    "endOffset": 20004,
                    "startOffset": 19997
                }
            },
            "secId": "s0005",
            "sentence": "The ODN 1826 used in this study is a class B CpG ODN with a preference for mouse TLR9 and contains a full phosphorothioate backbone with two CpG dinucleotides [21,22].",
            "startOffset": 19838,
            "title": "Introduction"
        },
        {
            "endOffset": 24197,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "TVGV-1-G vaccine was reconstituted to deliver 100 \u00b5g TVGV-1 protein and 100 \u00b5g GPI-0100 adjuvant in a volume of 100 \u00b5L per injection.",
            "startOffset": 24064,
            "title": "Immunization and tumor challenge"
        },
        {
            "endOffset": 46532,
            "parents": [],
            "secId": "s0070",
            "sentence": "These data do indicate, however, that the two adjuvants are not functionally equivalent in providing adjuvant activity to TVGV-1.",
            "startOffset": 46403,
            "title": "Discussion"
        },
        {
            "endOffset": 37898,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Both TVGV-1-C and TVGV-1-G vaccinated mice demonstrated statistically significant increases in the ratio of E7-specific CD8+ T cells to Tregs in the tumor microenvironment (Fig. 5f), which is often observed to be prognostically favorable for tumor clearance both in animal tumor models and in human cancers.",
            "startOffset": 37591,
            "title": "TVGV-1 vaccination results in increased lymphocyte effector cells within in the tumor microenvironment"
        },
        {
            "endOffset": 48858,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 48857,
                    "startOffset": 48853
                }
            },
            "secId": "s0070",
            "sentence": "For this study we tested vaccine efficacy in the C3.43 tumor model in which the entire native HPV16 genome was used to generate the tumor cell line [23].",
            "startOffset": 48705,
            "title": "Discussion"
        },
        {
            "endOffset": 23052,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Purity was determined to be >95% pure.",
            "startOffset": 23014,
            "title": "Mice, cell lines, antibodies, and reagents"
        },
        {
            "endOffset": 48539,
            "parents": [],
            "secId": "s0070",
            "sentence": "Only after adding the KDEL ER targeting signal was substantial anti-E7 immunity induced, and only after three doses were administered.",
            "startOffset": 48405,
            "title": "Discussion"
        },
        {
            "endOffset": 43276,
            "parents": [],
            "secId": "s0070",
            "sentence": "Consistent with other studies using GPI-0100 as an adjuvant, we show that the GPI-0100-adjuvanted TVGV-1 vaccine stimulated an anti-tumor CD8+ T cell response characterized by IFN\u03b3 and TNF\u03b1 secretion supporting a Th1-biased immune response, and furthermore we did not observe any toxicity associated with its use.",
            "startOffset": 42963,
            "title": "Discussion"
        },
        {
            "endOffset": 23297,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All in vivo studies were in compliance and approved by University of Southern California Institutional Animal Care and Use Committee (USC IACUC) and comply with the National Institutes of Health guide for the care and use of laboratory animals.",
            "startOffset": 23053,
            "title": "Mice, cell lines, antibodies, and reagents"
        }
    ],
    "docId": "S0264410X19305079",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Diane.DaSilva@med.usc.edu",
                "first": "Diane M.",
                "initial": "D.M.",
                "last": "Da Silva"
            },
            {
                "email": null,
                "first": "Joseph G.",
                "initial": "J.G.",
                "last": "Skeate"
            },
            {
                "email": null,
                "first": "Elena",
                "initial": "E.",
                "last": "Chavez-Juan"
            },
            {
                "email": null,
                "first": "Kim P.",
                "initial": "K.P.",
                "last": "L\u00fchen"
            },
            {
                "email": null,
                "first": "Jiun Ming",
                "initial": "J.M.",
                "last": "Wu"
            },
            {
                "email": null,
                "first": "Chia Mao",
                "initial": "C.M.",
                "last": "Wu"
            },
            {
                "email": null,
                "first": "W. Martin",
                "initial": "W.M.",
                "last": "Kast"
            },
            {
                "email": null,
                "first": "Kin Kai",
                "initial": "K.K.",
                "last": "Hwang"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.04.043",
        "firstpage": "2915",
        "issn": "0264410X",
        "keywords": [
            "CpG adjuvant",
            "GPI-0100 adjuvant",
            "HPV16-induced tumors",
            "Human papillomavirus",
            "Therapeutic vaccine"
        ],
        "lastpage": "2924",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease"
    }
}